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Ion channels are transmembrane proteins that allow and control the flux of ions 
(sodium, potassium, calcium, and chloride) across the plasma membrane. They are 
present in all cell types and play critical roles in a variety of biological processes. 
Historically, ion channels have always been an attractive target for the treatment of 
different pathologies mainly because numerous drugs can specifically bind ion channels 
modifying their functional activity.  
My PhD thesis addresses the role of two different ion channels in the two leading causes 
of death in the modern society: heart disease and cancer. 
The first part of this PhD dissertation, developed at University of Milan under the 
mentorship of Prof. Michele Mazzanti, focuses on understanding the role of CLIC1 
channels in glioblastoma cancer stem cells (CSCs). Glioblastoma is the most lethal 
among brain tumors. As other solid tumors, this cancer is composed of two cell types: a 
small population of cells able to self-renew and generate progeny (CSCs) and a larger 
population of differentiated cells (bulk cells). Glioblastomas are very aggressive tumors 
because of CSCs brain infiltration efficiency and resistance to chemotherapies. CLIC1 
is a metamorphic protein mainly present as a soluble form in the cytoplasm that is able 
to translocate to the plasma membrane in response to oxidative stimuli where it acts as a 
Cl- channel. Several forms of glioblastomas show a high level of expression of CLIC1 
compared to normal brains tissue. In electrophysiological experiments, overexpression 
of CLIC1 in murine CSCs were associated with a specific increase of the protein at the 
plasma membrane compared to normal stem cell (NSC). To study the relevance of 
CLIC1 we used CSCs isolated from human glioblastoma biopsies. By knocking down 
CLIC1 protein using siRNA viral infection (siCLIC1), we found that CLIC1-deficient 
cells proliferate less efficiently than control cells infected with siRNA for luciferase 
(siLUC). Since CLIC1 is a dimorphic protein we asked whether the reduction in 
proliferation was due to CLIC1 as ion channel. We performed perforated patches 
electrophysiological experiments for both siLUC and siCLIC1 cells. Cl- currents 
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mediated by CLIC1 were isolated using IAA94, a CLIC1 ion channel inhibitor. The 
results showed that siCLIC1 cells did not display IAA94-sensitive currents, while 
siLUC cells presented the CLIC1-mediated chloride current. These findings strongly 
suggest that CLIC1 ion channel activity is required in the proliferation activity of CSCs, 
and therefore represents a promising target direct in the reduction of CSC 
gliomagenesis. To target CLIC1 ion channel, the only effective drug so far identified is 
IAA94 which seems to be rather specific but toxic. For this reason we sought non-toxic 
drugs that could interact with CLIC1 ion channel. Epidemiological and preclinical 
studies propose that Metformin, a first-line drug for type-2 diabetes, exerts direct 
antitumor activity specifically on CSCs. Although several clinical trials are ongoing, the 
molecular mechanisms of this effect are unknown. To study Metformin's effect on 
CLIC1-mediated current (isolated with IAA94), we performed electrophysiological 
experiments from perforated patches using a glioblastoma U87 cell line. We constructed 
a dose response curve comparing Metformin effect on CLIC1 maximum current 
(isolated using IAA94) from which we calculated EC50 2.1 ± 0.4 mM. To validate the 
specificity of Metformin for CLIC1, we compared the extent of block of this drug to the 
one of IAA94 by sequentially adding the two inhibitors with either order. If the second 
drug perfusion did not show additional block, we can confirm that the two inhibitor 
share the same target. Interestingly, experimental data show that Metformin-mediated 
inhibition of CLIC1 is similar to IAA94 block, suggesting that they both act on CLIC1. 
Metformin displays antiproliferative activity mainly acting on CSC and not on the 
differentiated cells. Is this phenotype the result of different expression of CLIC1 in 
plasma membranes? Interestingly, the relative abundance of CLIC1-mediated current in 
CSCs was about three fold bigger than in differentiated cells, suggesting that CLIC1 
inhibition is relevant in the antiproliferative activity of Metformin. We sought to 
understand how Metformin bind the channel. Taking advantage of computational 
modeling and the available CLIC1 crystal structure, our collaborator predicted that the 
arginin 29 (R29) in the CLIC1 transmembrane domain may be part of the Metfomin 
binding site. We test this hypothesis in perforated patch clamp experiment using CHO 
cells stably transfected with CLIC1 wild type or CLIC1 R29A. The substitution of 
Arg29 in the putative CLIC1 pore region impairs Metformin modulation of channel 
activity. These results demonstrate that CLIC1 is required for human glioblastoma cell 
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proliferation. Furthermore, we identified CLIC1 as direct target of Metformin 
antiproliferative activity in human glioblastoma cells. These findings are paving the 
way for novel and needed pharmacological approaches to glioblastoma treatment. 
The second part of this PhD dissertation, focusing on cardiac arrhythmia, was 
developed at University of California, Los Angeles under the mentorship of Prof. 
Riccardo Olcese.  
The electrical activity of the heart originates from the rhythmic activity in the sinoatrial 
node (SAN) and spreads across the heart as a wave of depolarization (the cardiac action 
potential). While the normal ventricular cardiac action potential (AP) repolarizes 
monotonically, returning to the diastolic membrane potential, under certain pathological 
conditions the repolarization can be interrupted by sudden depolarizations called early 
afterdepolarizations (EADs), occurring during phase 2 or phase 3 of the AP. These 
events, observable at the cellular and tissue level, are recognized triggers of cardiac 
arrhythmias. In fact, EADs can generate a new AP that propagates across the heart 
disrupting the propagation of normal AP wave leading to ventricular tachycardia (VT) 
and ventricular fibrillation (VF). Ventricular fibrillation is the most commonly 
identified arrhythmia in sudden cardiac death (SCD), one of the leading causes of death 
in the United States. 
This project investigated the relevance of the voltage gated L-type calcium channel 
(CaV1.2) in the etiology of EADs of the cardiac action potential. EADs are largely 
induced by the reactivation of L-type Ca2+ currents (ICa,L) that occurs at the range of 
membrane potential from 40 to 0 mV, called window current region. To study the 
dependence of EADs on the biophysical properties of L-type Ca2+ current (ICa,L) we 
adopted a hybrid biological–computational approach: the dynamic clamp technique. 
Under dynamic clamp it was possible to replace the native ICa,L of a ventricular myocyte 
with a computed ICa,L defined by programmable parameters. We previously identified 
three L-type Ca2+ channel (LTCC) biophysical parameters that effectively suppress 
EADs induced by oxidative stress or hypokalemia by preventing ICa,L reactivation in the 
window current region. Specifically, EADs were potently suppressed by: i) a ~5 mV 
depolarizing shift of the steady-state activation curve, ii) a ~5 mV hyperpolarizing shift 
of the steady-state inactivation curve or iii) a reduction of the non-inactivating pedestal 
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component. Importantly, these changes did not significantly alter the peak ICa,L or Ca2+ 
transient amplitude during the action potential. Since LTCCs are multiprotein 
complexes in which CaVβ subunits modulate the gating properties and voltage 
dependence of the pore-forming CaV1.2 α1C subunit, we explored whether modifying 
LTCC β subunit composition is a suitable therapeutic strategy to suppress EADs. 
Voltage clamp experiments, in which we expressed Cav1.2 α1c with different β 
subunits, showed that subunit subtypes β2a and β2b, which are abundantly expressed in 
ventricular myocytes, give rise to LTCCs with voltage-dependent properties favoring 
EADs formation.  
Accordingly, we tested an adenovirus-based shRNA delivery strategy to reduce β2 
expression in primary ventricular myocyte cultures; the rationale being that a LTCC 
population in a cell with a smaller proportion of β2a- and β2b-containing channels should 
generate ICa,L with an overall voltage dependence disfavorable to EADs emergence. The 
simultaneous partial knock down of β2a and β2b shifted the whole-cell ICa,L steady-state 
activation curve to more depolarized potentials by ~4 mV without significantly 
affecting peak ICa,L. A “narrower” ICa,L window current could diminish the probability of 
EADs formation by preventing channel reopening. In congruence with the dynamic 
clamp results, EADs occurrence under oxidative stress (H2O2) was potently prevented 
in rabbit ventricular myocytes with β2 knock-down (no EADs observed). Conversely, 
control myocytes from the same batches exhibited significant action potential 
prolongation and all cells developed EADs after H2O2 exposure. These findings 
demonstrate that manipulation of the subunit composition can be an effective strategy 
for modifying the steady-state properties of ICa,L. Thus, our results highlight the use of 










Functional Role of CLIC1 in the Pathophysiology 





1.1.1. Neuronal Stem Cells 
Neural stem cells (NSCs) are a rare population of cells in the central nervous system. 
They are self-renewing and multipotent cells active in the development and repair of 
damaged components (Stiles and Rowitch, 2008). Thus, they have the capacity to 
differentiate into unipotent precursors which give rise to neurons, astrocytes and 
oligodendrocytes (Figure 1). Neogenesis of cells in the central nervous system (CNS) 
persists throughout life in certain brain regions such as the subventricular zone of the 
lateral ventricle and the dentate gyrus (Reynolds and Weiss, 1992). These regions have 
a network of microvasculature that provides the nutrients needed and factors for the 
maintenance of stem cells in a quiescent state (Gilbertson and Rich, 2007; Jones and 
Holland, 2010; Sanai et al., 2005). These special areas called vascular niches consist of 
endothelial cells, astrocytes, microglia and muscle cells that play a protective role for 
neural stem cells (Jones and Holland, 2010). 
  
 
1.1.2. Cancer Stem Cells 
Cancer stem cells (CSC) are defined, in analogy to NSC, as cells that possess ability of 
self-renew and differentiate into other, more specialized cancer cell types 
(multipotency) (Stiles and Rowitch, 2008; Huse and Holland, 2010; Baccelli and 
 
Figure 1. Neural stem-cell generates neuronal and glial progenitor cells, which 
subsequently generate the three differentiated cell types of the central nervous 
system: neurons, astrocytes, and oligodendrocytes (Sanai et al., 2005). 
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Trumpp, 2012). Similar to neuronal stem cells, brain CSCs express stemness markers 
(such as nestin, CD133), are localized in perivascular niches and grow as neurospheres 
in vitro (Calabrese et al., 2007; Huse and Holland, 2010; Jones and Holland, 2010; 
Charles and Holland, 2010; Stiles and Rowitch, 2008). However unlike neuronal stem 
cell, they possess cancer properties, such as karyotypic anomalies or genetic mutation, 
unlimited proliferation and ability to reconstitute the original tumor upon 
transplantation (Huse and Holland, 2010).  
In 1997 Bonnet and Dick showed for the first time the existence of a restricted 
population of cancer stem cells in human acute myeloid leukemia. In particular they 
identified for the first time that a subtype of cells, namely CSC were able to induce and 
recapitulate the heterogeneity of the original tumor through serial transplantations in 
mouse xenograft model (Bonnet and Dick, 1997). The existence of CSCs was then 
proved in many solid and liquid cancers including brain tumors (Singh et al., 2007; 
Singh et al., 2004; Galli et al., 2004).  
During the last two decades a revolutionary hypothesis about the tumor composition has 
been theorized. “The cancer stem cell theory” in fact proposes that among all the tumors 
cells, only relatively small subset has stem cell-like properties. Therefore the tumor has 
hierarchical organization that consists of a rare tumor-initiating and propagating cancer 
stem cell (CSCs) and a larger population of differentiated cells without proliferative 
capacity (bulk) (Reya et al., 2001). The maintenance of the stem core can be achieved 
by two types of cell division: i) asymmetric division, by which the stem cell gives rise 
to a stem cell daughter, also capable of making self-renewal, and a cell that will 
encounter differentiation or ii) symmetric division, in which the stem cell divides give 
rise to two daughters or two stem progenitors mature identical to each other (Vescovi et 
al., 2006). 
The origin of CSCs remains controversial. Cancer stem cell can arise from a series of 
mutations that occur in few or even single founder cells that confer unlimited and 
uncontrolled proliferation potential (Vescovi et al., 2006; Hanahan and Weinberg, 
2000). Different studies demonstrate that cancer stem cells have a critical role in the 
formation, development and recurrence of the tumor (Baccelli and Trumpp, 2012). In 
addition, CSCs are predicted to be difficult targets for cancer therapeutics because: they 
cycle slowly, they highly express transport mechanisms that effectively extrude drugs, 
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they strongly activate anti-apoptotic pathways of DNA repair, and they may not express 
the oncoproteins targeted by the new generation of drugs. All these features make this 
cells resistant to conventional chemo and radio therapies currently in use (Stiles and 
Rowitch, 2008; Bao et al., 2006). 
 
1.1.3. Glioblastoma 
Gliomas are the most common primary tumor in the central nervous system in adults 
and represent 31% of all brain and central nervous system (CNS) tumors diagnosed in 
the United States, and 81% of malignant brain and CNS tumors (Cohen and Colman, 
2015). They originate from the neoplastic degeneration of glia cells, including 
astrocytes, oligodendrocytes and ependymal cell (Sanai et al., 2005; Huse and Holland, 
2010; Chen et al., 2012). These tumors are classified by World Health Organization 
(WHO) in four classes I to IV grade following histological criteria. The increase of 
degree reflects the increase of aggressiveness of the tumor and the duration of the 
prognosis (Denysenko et al., 2010; Huse and Holland, 2010; Maher et al., 2001). 
Although gliomas are typically malignant, not all types consistently behave in a 
malignant fashion. The heterogeneity of gliomas (in terms of histology, grade, clinical 
outcomes, and genomics) increases the complexity of risk factor research in this tumor 
type. The more aggressive tumor and, unfortunately, more common is the glioblastoma 
(grade IV) which shows uncontrolled proliferation, neovascularization, infiltration and 
necrosis.Glioblastoma (GBM) is the most aggressive and lethal among brain tumors in 
adults, and it still represents a tremendous clinical challenge. GBM has the poorest 
overall survival, with <5 % of patients surviving 5 years after diagnosis (Jones and 
Holland, 2010). Unfortunately, the occurrence of the GBM is more frequent than all the 
other glioma types, as reported in Figure 2. The life expectancy for patients diagnosed 
with GBM is between 12 and 15 month (Chamberlain, 2010; Maher et al., 2001). The 
reason for this poor prognosis mainly resides in the fact that GBMs are resistant to 
radiotherapy and chemotherapy. Moreover, due to its high invasiveness in the brain 




Treatment involves a three-pronged approach, which consists of maximal tolerable 
surgical resection followed by radiation and chemotherapy. (Lefranc et al., 2005; 
Furnari et al., 2007). Little is known about the molecular mechanisms underlying the 
genesis and the progression of GBM, which is characterized by the high propensity to 
infiltrate throughout the brain.  
GBM is a highly heterogeneous tumor that contains multiple differentiated and 
undifferentiated cell types. In general, this elevated cellular and molecular heterogeneity 
makes even more difficult the development of a unique effective therapy (Huse and 
Holland, 2010). They are typically highly vascularized tumors often with extensive 
capillary beds that can provide a similar vascular niche for CSCs to reside in, similarly 
to neuronal stem cell (Calabrese et al., 2007). The new blood vessels favor tumor 
growth and infiltration by providing oxygen and nutrients to tumor cells (Denysenko et 
al., 2010; Sanai et al., 2005; Jones and Holland, 2010). Differently from other solid 
tumors, gliomas do not take advantage of the linfatic and blood streams to spread and 
form metastasis outside of the CNS (Maher et al., 2001). The heterogeneity of 
glioblastoma tumors and their tendency towards fast malignant progression, are coupled 
with the ability of glioma cells to migrate away from a tumor mass into normal brain 
tissue where they generate multiple new foci and recurrent growth (Denysenko et al., 
2010; Huse and Holland, 2010; Sanai et al., 2005).  
 
Figure 2. Distribution of primary brain tumor new primary gliomas in USA between 
2007 and 2011. The glioblastoma account for more than 50% of all the gliomas 
(CBTRUS Statistical Report: NPCR and SEER, 2007–2011).  
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The origin of GBM has been an issue for discussion. Different studies suggest that 
GBM derive from the transformation of different cells, such as neural stem cells (NSCs) 
or glial progenitor (committed progenitors) or astrocytes. In general, cancer cells of 
origin are normal cells in which tumorigenic mutations first occur and accumulate to 
form a malignancy (Chen et al., 2012). In neuronal stem cells and progenitor cells, the 
oncogenic process can be viewed as a lack of regulatory mechanisms that control the 
ability of self-renewal and/or differentiation (Vescovi et al., 2006). Furthermore, it has 
been hypothesized that glioma originates from transformation of astrocytes, as the only 
known replication-competent population in the SNC. In this case the malignant 
transformation requires a ‘‘dedifferentiation’’ process in by which cells regain to 
immature glial and progenitor properties (Sanai et al., 2005; Stiles and Rowitch, 2008). 
To explain how GBMs initiate and develop, to date two alternative models are present 
(Figure 3). The stochastic model proposes that tumor cells are heterogeneous, and 
virtually all of them can function as a tumor-founding cell. On the other hand, the 
hierarchical model implies that only a small subpopulation of tumor stem cells can 
proliferate extensively and sustain the growth and progression of a neoplastic clone 
(Reya et al., 2001). The latter hypothesis fits with the cancer-stem-cell theory (Vescovi 




Figure 3. Tumor initiation model. A)Cancer cells of many different phenotypes 
have the potential to proliferate extensively, but any one cell would have a low 
probability of exhibiting this potential in an assay of clonogenicity or 
tumorigenicity. B) Most cancer cells have only limited proliferative potential, but 
a subset of cancer cells consistently proliferate extensively in clonogenic assays 
and ability to generate new tumors (Reya et al., 2001).  
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1.1.4. Chloride channels and glioblastoma
Ion channels are transmembrane proteins that allow and control the flux of ions 
(sodium, potassium, calcium, chloride and protons) across the plasma membrane. They 
are present in all cell types and play critical roles in a variety of biological processes, 
such as muscle contraction, cell excitability, hormone secretion, mechanosensitivity. In 
recent decades, growing scientific evidence supports the role of ion channels also in 
tumor development and growth (Fraser and Pardo, 2008). It has been shown that 
different types of ion channels play relevant roles in all six cancer hallmarks: 1) self-
sufficiency in growth signals, 2) insensitivity to antigrowth signals, 3) avoidance of 
programmed cell death (apoptosis), 4) unlimited replicative potential, 5) angiogenesis 
and 6) tissue invasion and metastasis (Figure 4) (Prevarskaya et al., 2010; Fraser and 
Pardo, 2008). 
 
In particular, tumor invasiveness appears to be associated with K+ and Cl- channels 
upregulations (Cuddapah et al., 2014) (Figure 5). These channels are required for 
efficient regulation of the cell volume by creating local osmotic gradients that facilitate 
the swelling or shrinking of cells (Cuddapah et al., 2014). The Chloride channel family 
is composed by four different classes: Voltage–dependent Chloride channel (ClC), 
Calcium-Activated Chloride Channels CLCA, Cystic Fibrosis Transmembrane 
conductance Regulator (CFTR), and Chloride Intracellular Channels (CLIC). Chloride 
channels are ubiquitously expressed and localized both in plasma membrane and in 
 
Figure 4. Different types of ion channels are involved in each of the six cancer 




intracellular organelles. The different families of chloride channels participate in the 
tumorigenesis process of different cancers.  
Specifically in glioblastomas, mainly two types of Cl- channels have been reported to be 
relevant for glioma invasion and proliferation: ClC and CLIC. 
Similar to immature neurons, glioblastoma cells maintain high intracellular Cl- (80–100 
mM) (Habela et al., 2009; Sontheimer, 2008). Thus, even at a relatively depolarized 
resting potential (~ -40 mV), opening of Cl- channels causes Cl- efflux (Sontheimer, 
2008), followed by water, in turn inducing cell shrinkage and likely tissue infiltration.  
 
Indeed, three members of ClC class (ClC-2, -3 and 5) are expressed in glioma cell 
membranes and they are localized in the lamellipodia during migration process (Olsen 
et al., 2003). 
 
ClCs participate in glioblastoma cells insomuch as now a generic blocker of ClC class 
of channel, chlorotoxin (CTX) is now in phase I/II clinical trial for gliomas treatment 
(Cheng et al., 2014). 
Alike migration/invasion process, cell proliferation also requires considerable 
structural/volume changes that are mediated by activity of different channels that allow 
the progression and conclusion of the cell cycle (Lang et al., 2005). Correct progress 
through cell cycle is ensured by checkpoint controls that monitor DNA integrity and the 
 
Figure 5. K+ and Cl− efflux helps glioma-cell shrinkage. To reduce their 
cytosplasmic content, cells release Cl− and K+ through ion channels, and water 
follows passively through water channels or aquaporins. For this mechanism to 
function, cells must accumulate Cl− and K+ above their respective electrochemical 
gradients. This is accomplished by the combined activity of the NKCC Cl− 
transporter and the Na+–K+ ATPase for K+ ions (McFerrin and Sontheimer, 2006). 
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completion of each molecular events before allowing transition to the next phase 
(Becchetti, 2011) (Figure 6).  
 
In eukaryotic cells, the main checkpoints are placed at the G1/S transition, in late S 
(DNA synthesis) phase, at mitosis (M) entry and at the metaphase to anaphase transition 
are highly regulated by different channel (Figure 6). Little is known, however, about the 
involvement of chloride channel in cell cycle. Previously, Habela and colleagues found 
that ClC-3 channel activity is important for the regulation of glioma cell cycle (Habela 
et al., 2008). The activity of the channel is mainly upregulated during the M phase and 
during this phase the protein localizes both at the plasma membrane and at the mitotic 
spindles (Habela et al., 2008). In these cells, knocking down ClC-3 considerable delays 
mitosis impairing cell proliferation (Wang et al., 2002). 
The role of CLIC1 in tumors will be discussed in the session “CLIC1 in tumors”. 
 
1.1.5. The chloride intracellular channel 1 (CLIC1)
The chloride intracellular channel (CLIC) protein family has been the last discovered 
and still largely underexplored. Until now seven members of the family have been 
identified: CLIC1 , CLIC2 , CLIC3 , CLIC4 , CLIC5a , CLIC5b and CLIC6 (Singh, 
2010). They are highly conserved class of proteins expressed both in the 
 
Figure 6. Schematic relation between ion channels and the main cell cycle 
checkpoints. Four main checkpoints have been identified in eukaryotic cells: at the 
G1/S transition, in late S, at the G2/M transition and at the metaphase to anaphase 
transition (Becchetti, 2011).  
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plasmamembrane and intracellular organelles. The CLIC family is defined by a 
conserved, approximately 230 amino acid core sequence which comprises the C-termini 
of all known CLICs. Sequences amino-terminal to the core region are divergent both in 
sequence and in size. Furthermore, they share structural homology with members of the 
superfamily of omega glutathione S-transferase (ΩGST) also with regard to the highly 
conserved active site binding to glutathione (GSH) in the N-terminal domain ( in CLIC1 
is the Cysteine 24 ) (Littler et al., 2010). Recently, it has been demonstrated that CLICs 
soluble form have glutaredoxin-like glutathione-dependent oxidoreductase enzymatic 
activity that may be important for protecting the intracellular environment against 
oxidation in physiological (Al Khamici et al., 2015). A unique feature of CLIC proteins 
is their ability to exist in two different forms: a soluble globular form in the cytoplasm 
and an integral membrane protein, suggested forming functional ion channels. 
 
In 1989, Landry and Al Awqati isolated the first protein of this family called p64 (or 
CLIC5b). It was isolated from bovine tracheal apical epithelium and kidney cortex 
microsomal membrane fractions showed chloride-selective channel function in lipid 
bilayers (Landry et al., 1993). The localization of these proteins is mainly intracellular, 
some are identified for example in the mitochondrial membrane (CLIC4), in the nuclear 
(CLIC1), in the endoplasmic reticulum (CLIC4), in the Golgi (CLIC4) and secretary 
vesicles (CLIC5b) (Harrop et al., 2001). 
 
The cloning of p64 facilitated the identification of homologous proteins in mammalian 
tissues and lately in the ‘90s NCC27 (or CLIC1) was cloned in human monocytic cell 
line (Valenzuela et al., 1997). CLIC1 is a small protein composed by 241 aminoacids, 
with a molecular weight of 27 KDa (Valenzuela et al., 1997). The crystal structure of 
the soluble form of the protein has been resolved few years ago by Harrop and 
colleagues (Harrop et al., 2001). The N-terminus and the C- terminus domains are 
connected by a proline-rich region, in which proline 91 has been suggested to have a 
main role in the changes from the soluble to the membrane-inserted form of the protein, 
due to its change from cis to trans configuration (Harrop et al., 2001) (Figure 7). 
Furthermore, CLIC1 has a reduced glutathione (GSH)-binding site in its N-terminal 
domain, which render this protein sensitive to the oxidative state of the cell.  
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In fact, it has been shown that changes in the cellular redox state determine a reversible 
transition of CLIC1 protein between a reduced, soluble monomeric state and an 
oxidized, soluble dimeric state (Littler et al., 2004). However, a different study suggests 
that the dimerization process during oxidation is not necessary for the insertion of the 
protein into membranes (Goodchild et al., 2009). In this model, CLIC1 monomer 
interact by itself with the membrane and only successively the oxidation promotes the 
structural changes that allow the protein to cross the membrane. 
 
Studies on the localization of CLIC1 showed that this protein is found mainly in the 
nuclear membrane and in the nucleoplasm even though fractions of this protein are also 
present in the cytoplasm and in the plasma membrane (Tonini et al., 2000; Valenzuela 
et al., 1997; Valenzuela et al., 1997). To understand the characteristics of the ion 
channel, biophysical experiments were carried out on CLIC1 transfected CHO-K1 cells 
through cell and nuclear patch clamp (Tonini et al., 2000).  
By transfecting these cells with CLIC1 tagged with FLAG epitope tag either a N- or C-
terminal they demonstrate with the antibody anti-FLAG, that CLIC1 spans the plasma 
membrane with the C terminus (Tonini et al., 2000). It has also been proven that CLIC1 
purified protein can form a chloride channel in artificial bilayer with characteristics very 
similar to those observed in CHO cells transfected in inside-out configuration (Warton 
et al., 2002; Singh et al., 2007; Tulk et al., 2002). The insertion of the channel in the 
membrane appears to be facilitated by the oxidation but also by other factors, for 
 
Figure 7. CLIC1 is a small protein of 241 amino acids. In light blue is highlighted 
the hypothetical transmembrane domain (image created with PyMol )  
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example pH acidification. In experiments of artificial bilayer, using solutions with acid 
pH, it has been shown that CLIC1 has a higher probability of entering into the lipid 
bilayer (Warton et al., 2002). Recently, it has been demonstrated the relevance of Glu85 
and Glu228 as a “pH-sensor residues” that contribute to the pH-response (Cross et al., 
2015). CLIC1 single channel conductance in 140 mM KCl symmetric solution is 
approximately 30 pS (Tulk et al., 2002; Warton et al., 2002). To further support the ion 
channel nature of CLIC1, it has been reported that a single point mutations (C24A, 
R29A, K37A) in CLIC1 putative transmembrane region results in alterations of the 
electrophysiological characteristics of the channel (Singh and Ashley, 2006; Averaimo 
et al., 2013).The only effective channel blocker so far identified is the Indanyloxyacetic 
acid 94 (IAA94), with an EC50 of 8.6 μM (Tulk et al., 2000) whereas DIDS (4'-2,2'-
disulfonic Diisothiocyanatostilbene-acid disodium salt hydrate), another chloride 
channel blocker, has no effect on the conductance of this channel (Valenzuela et al., 
2000).  
CLIC1 is expressed in different epithelial and non-epithelial cell types where it shows 
tissue- and cell-specific patterns of subcellular localization (Ulmasov et al., 2007). 
Although CLIC1 clearly can function as a channel in vitro, the role of CLIC1 in normal 
physiology remains uncertain. In 2010, Qiu and collegues generated a Clic1 KO mouse 
that does not show any embryonic lethality but only a mild bleeding disorder and 
decreased platelet activation (Qiu et al., 2010). Moreover, in a mouse model of 
Alzheimer disease, CLIC1 is mainly localized in the plasma membrane of activated 
microglia (Figure 8). Our laboratory has previously shown that blockade of CLIC1 
functional expression with specific inhibitors or its downregulation by small 
interference RNA, impairs the production of reactive oxygen species (ROS), limiting 
the detrimental effects of microglia over activation (Milton et al., 2008). Therefore the 
reduction of CLIC1 activity, may limit neurodegeneration without affecting the 
phagocytic ability of microglia (Paradisi et al., 2008). Furthermore, it has been 
demonstrated that CLIC1 ion channel is required for maintaining the morphology and 




1.1.6. CLIC1 in tumors 
CLIC1 protein levels are reportedly increased in different cancers, such as: human 
breast ductal carcinoma (Wulfkuhle et al., 2002), gastric cancer (Chen et al., 2007), 
gallbladder metastasis (Wang et al., 2009), colorectal cancer (Petrova et al., 2008), 
nasopharyngeal carcinoma (Chang et al., 2009), ovarian cancer (Tang et al., 2012), 
hepatocellular carcinoma (Wei et al., 2015), and high-grade gliomas (Wang et al., 
2012). All these analyses propose CLIC1 as a tumor marker, sometimes detectable even 
in the plasma of patients and so very useful in the clinic.  
CLIC1 is overexpressed in brain tumors compared with normal brains and the 
expression at both mRNA and protein levels increasing along with WHO tumor grades 
and reaching the highest expression level in glioblastoma (Wang et al., 2012).  
CLIC1 is a dimorphic protein and under oxidative stress is mainly localized at the 
plasma membrane (Milton et al., 2008). Thus, CLIC1 appears to have a main role in all 
the diseases that involve oxidative stress, including tumors (Averaimo et al., 2010). 
Furthermore, in CHO-K1 cell line CLIC1 chloride current varies according to the stage 
of the cell cycle and it is mainly expressed in the plasma membrane of cells in G2/M 
phase (Valenzuela et al., 2000). Since oxidative fluctuations drive the cells through the 
cell cycle phases (Menon and Goswami, 2007), it is not surprising that CLIC1 may be 
 
Figure 8. Immunolocalization of CLIC1 (green, antibody directed against the N-
terminus of the protein) in BV2 cells (nuclei are stained in blue, DAPI). Following 
β-Amyloid (Aβ) stimulation, which induces oxidative stress, CLIC1 translocates 










Metformin (1,1-dimethylbiguanide), a biguanide derivate, was originally described in 
1921 (Werner and Bell, 1921). It is a small-molecule weight (129.2 KDa), water-
soluble, which at physiological pH-values exists as an organic cation. Although the 
molecular weight and protein binding of Metformin are low, it poorly diffuses passively 
through membranes (Detaille et al., 2002). OCT1 and OCT2 are the main active 
transporters, which facilitate the transport of Metformin across the liver, intestine and 
kidney tissues (Shu et al., 2007; Graham et al., 2011). Metformin is the most widely 
used drug for treating patients with type 2 diabetes (prescribed to approx. 120 million 
patients with type 2 diabetes/year) (Pollak, 2012). Although Metformin has been widely 
used as a very effective anti-diabetic drug for many decades, the exact molecular 
mechanism(s) of Metformin action against diabete is not completely understood (Bao et 
al., 2014). 
Metformin alleviates hyperglycemia by reducing hepatic glucose production 
(gluconeogenesis) and increasing glucose utilization (glucogenolysis). Thus Metformin 
is antihyperglycemic (not hypoglycemic) as it does not stimulate insulin release from 
the pancreas and generally does not cause hypoglycemia, even in large doses (Inzucchi, 
2002). Metformin metabolic effects mainly rely on mitochondrial activity: it decreases 
ATP production and activates AMP-activated protein kinase (AMPK), thus regulating 
gluconeogenesis and fatty acid synthesis (Hardie et al., 2012). Due to its very cost-
effective and safe properties, Metformin has been widely prescribed as the first line of 
medication as an anti-diabetic drug (Bao et al., 2014). Importantly, the long-term use of 
Metformin in diabetic patients is associated with minor adverse effects (Bolen et al., 
2007). Metformin is absorbed mainly from the small intestine and its oral bioavailability 
is 50-60%. The peak plasma concentration is reached within 1-3 hours after oral intake 
of immediate release tablets and within 4-5 hours after oral intake of extended release 
tablets (Tucker et al., 1981). The half-life of elimination is about 6.5 hours. Metformin 
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is not metabolized, and 90% is excreted unchanged into the urine by tubular secretion. It 
is also able to cross the blood-brain barrier (Sato et al., 2012; Labuzek et al., 2010). 
 
1.1.8. Metformin and Glioblastoma 
Epidemiological studies reported that Metformin is associated with reduced cancer 
incidence (Evans et al., 2005) and mortality (Bowker et al., 2006) and increases the 
number of breast carcinoma patients obtaining complete response to neo-adjuvant 
therapy (Jiralerspong et al., 2009).  
Metformin controls cell proliferation and tumor growth, but the molecular mechanism 
by which this compound reduces tumor development is not clear (Viollet et al. 2012). 
Metformin antitumorigenic effects are thought to be independent of its hypoglycemic 
actions (Kourelis and Siegel, 2012). The anticarcinogenic effects of this drug have been 
attributed to several mechanisms: (1) activation of LKB1/AMPK pathway, (2) induction 
of cell cycle arrest and/or apoptosis, (3) inhibition of protein synthesis, (4) reduction in 
circulating insulin levels, (5) inhibition of the unfolded protein response (UPR), (6) 
activation of the immune system, and (7) eradication of cancer stem cells (Kourelis and 
Siegel, 2012). 
Isakovic and collegues demonstrated antiproliferative effect of Metfromin using rat and 
human glioma cell line. They establish that Metformin causes cell cycle arrest and 
apoptosis of glioma cells through unique AMPK-dependent mechanisms (Isakovic et 
al., 2007). Furthermore, Würth and colleagues using glioblastoma cancer stem cell 
(CSC) isolated from patients demonstrated that Metformin exerts antiproliferative 
activity on glioblastoma cells, showing a higher specificity toward normal stem cell 
(umbilical cord-derived mesenchymal stem cells) and differentiated cells (Wurth et al., 
2013; Wurth et al., 2014). Metformin also decreases spherogenesis of CSCs mainly 
acting on the inhibition of Akt pathway. Furthermore Sato and colleagues identified 
Metformin as a therapeutic activator of the transcription factor forkhead box O3 
(FOXO3) (Sato et al., 2012). This activation of FOXO3 by Metformin promotes the 
differentiation of glioblastoma CSCs into non-tumorigenic cells. The heterogeneity of 
the reported mechanisms of action of Metformin can imply that is a promiscuous drug 
24 
 
acting on multiple pathways. Furthermore there are several on going and upcoming 
clinical trials, including glioma, on the use of Metformin for cancer treatment and 
prevention (Kourelis and Siegel, 2012).  
 
 
This thesis focuses on the pivotal role of CLIC1 ion channel as a molecular target for 
anti-proliferation activity of human glioblastoma cancer stem cell, highlighting the 






1.2.1. Human glioblastoma cancer stem cell 
Tumor biopsies classified as glioblastoma grade IV (GBM IV) were collected from 
consenting patients at the Istituto Neurologico Carlo Besta, Department of 
Neurosurgery, Milan (Italy) and at Azienda Ospedaliera Universitaria "San Martino", 
Department of Neurosurgery, Genoa (Italy). The tissues were enzymatically digested 
with papain (2mg/ml) (Worthington Biochemical, Lakewood, NJ) at 37°C and 
mechanically dissociated until a single cell suspension was achieved, as previously 
described by Vescovi and colleagues (Vescovi et al., 2006) (Figure 9). 
 
Glioblastoma cancer stem cell: human and murine GBM cancer stem cell (CSC) and 
normal stem cell (NSC) were grown in stem cell permissive medium composed by 
NeuroCult medium (StemCell Technologies, Vancouver, BC, Canada) supplemented 
with 20 ng/ml epidermal growth factor (EGF), 10 ng/ml basic fibroblast growth factor 
(bFGF) (PeproTech, Rocky Hill, NJ), and 0.0002% heparin (Sigma-Aldrich, St. Louis, 
MO) (Ortensi et al., 2012). The CSCs were grown in suspension were they form a 
spheroid aggregates (neurospheres), each deriving from a single cancer stem cell. 
Neurospheres can be further mechanically dissociated into a single-cell suspension and 
 
Figure 9. Human brain tumor biopsys were dissociated and cultured in a specific 




then re-plated in fresh medium to produce secondary neurospheres every 5-10 days. 
This process can be repeated several times (Figure 9). The absence of serum in the 
neurosphere medium allows the isolation and propagation of cancer stem cell only. To 
induce the differentiation of GBM CSC cell, the single CSC were cultured in growth 
factor-deprived medium (no EGF, bFGF) containing 10% fetal bovine serum (FBS, 
Lonza) for at least 2 weeks. 
 
1.2.2. Other cell cultures 
U-87MG (human primary glioblastoma) and CHO (Chinese hamster ovary) cell line 
were grown under standard condition with DMEM+10%FBS. CLIC1 wild type (CLIC1 
wt) and R29A (CLIC1 R29A) mutant were stably transfected in CHO cells using 
FuGENE Reagent (Roche). N-terminal FLAG-tagged human CLIC1 (WT) or its R29A 
mutant cloned in pIRES2-EGFP vector (Clontech Laboratories Inc., San Jose, CA). The 
pIRES2-EGFP plasmid used for these experiments contains the internal ribosome entry 
site (IRES), which permits both the gene of interest and the gene reporter (EGFP) to be 
translated as separate proteins. 
 
1.2.3. Clonogenic Assay 
To measure the clonogenicity, cells were resuspended in Dulbecco’s modified Eagle 
medium/F12 medium containing methylcellulose (StemCell Technologies, Vancouver, 
BC, Canada) and seeded on 35-mm culture plates (3000 cells per dish). A minimum of 
three plates per condition was used. Two weeks after plating, the number of clones was 
counted. 
 
1.2.4. Quantitative Real Time Polymerase Chain Reaction (qRT-
PCR) 
Total RNAs from glioblastoma cell were isolated by RNAeasy Mini kit (Quiagen, 
Valencia, CA). RNAs from each sample (1µg) were retrotranscribed using ImProm-II 
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Reverse 2 Transcriptase (Promega, Madison, WI) at the following temperature steps: 
25°C for 5’, 42°C for 60’, 70°C for 10’. Quantitative real time PCR (qRT-PCR) 
analysis was then performed by 7,500 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA) with Syber Green PCR Master Mix (Applied Biosystems, 
Foster City, CA). The sequence of primers was the following:  
CLIC1 fw: 5’-GTTGACACCAAAAGGCGG-3’, rev: 5’-TCTCCAGATTGTCATTGAGTGC-3’;  
TBP fw:5’-TGCACAGGAGCCAAGAGTGAA-3’, rev: 5’-CACATCACAGCTCCCCACCA-3’;  
HPRT1 fw:5’-TGACCTTGATTTATTTTGCATACC-3’, rev: 5’-CGAGCAAGACGTTCAGTCCT-3’. 
 
1.2.5. Lentiviral infection 
RNA interference (RNAi) is a biological process in which small RNA molecules, called 
siRNAs, inhibit the expression of a gene of interest, by causing the destruction of the 
specific mRNA. Experimentally, this process can be induced by introduction of 
synthetic small interfece (siRNAs) into the cells or by intracellular generation of siRNA 
from vector driven expression of the precursor small hairpin (sh) RNAs. shRNA has 
been shown to be more effective and potent in silencing genes. In these “method”, a 
double-stranded oligonucleotide containing the siRNA sequence linked by a ~9 
nucleotide loop is cloned in plasmid or viral vectors to endogenously express shRNA 
which is subsequently processed in the cytoplasm to siRNA. To delivery the plasmid 
into the cell we used a Lentiviruses. This type of virus is suited for long-term shRNA 
expression and gene silencing since the viral DNA gets incorporated in the host 
genome. 
The short hairpins specific to human CLIC1 (5’-GATGATGAGGAGATCGAGCTC-
3’) and to firefly luciferase (5’-CGTACGCGGAATACTTCGA-3’) mRNAs were 
cloned into the PLentiLox 3.7 lentiviral vector using the XhoI/HpaI sites. The 
PLentiLox 3.7 lentiviral vector also includes the puromycine gene to select infected 
cells and the Green Fluorescent Protein (GFP) gene to evaluate transduction efficiency. 
Lentiviral and packaging plasmids (vpMDLg/pRRE, pRSV-REV and pMD2G) were 
amplified in the E.Coli-strain Top10 and purified using a QUIAGEN MAXI KIT. HEK 
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293T cells were used to amplify the viral particles and they were grown in IMDM 
(Iscove’s Modified Dulbecco’s Medium, plus Glutamax, Invitrogen) with 10% FBS and 
25 U/ml Penicillin/Streptomycin. HEK 293T cells were co-trasfected with all the 
plasmids using the calcium phosphate method according to established procedures 
(TronoLab). The viral particles were collected and concentrated using PEG-it. The 
transducing unit (TU) concentration was then determined by GFP expression. The viral 
suspension was used to infect dissociated CSCs from human GBM (104 TU/µl). 72 
hours after infection, cells were positively selected with 1.5 mg/ml puromycine. 
1.2.6. Western Blot 
Cell samples were collected by centrifugation and pellets were lysated on ice in 50-100 
µl of lysis buffer (50 mM Tris–Cl buffer, 10 mM CaCl2, 5mM EGTA, 250 mM NaCl , 
10% Glycerol, 1% triton-x 100, pH 8) containing a cocktail of proteinase inhibitors (50 
mM NAF, 10 mM NAPP, 10mM NaOrtoV, 0.1mg/ml PMSF, Leupeptin , Apoprotinin 
). Concentration of protein lysates was assessed by Bradford assay (Biorad). 
Membrane/cytoplasm fractions were obtained using the “Membrane protein extraction 
kit” (Thermo Scientific), following the manufacturer’s instructions. Each lysate (10 µg) 
was loaded onto a SDS-polyacrylamide gel electrophoresis (PAGE) under reducing 
conditions, and resolved proteins were transferred onto Nitrocellulose membranes 
(Protran ®) of 0.2 μm pore size. Membranes were incubated overnight at 4°C with anti-
CLIC1 mouse monoclonal antibody, anti-Vinculin, anti-GFAP, anti-tubulin diluted in 
Tris-Buffered Saline and Tween 20 (TBS-T [50mM Tris, 150mM NaCl, 0.05% Tween 
20]) supplemented with 5% Milk Powder. Antibody binding was assessed by 
horseradish peroxidase (HRP)-conjugated secondary antibody (Sigma Aldrich, 1:10000 
dilution). Immunoreactive bands were detected with enhanced chemiluminescence 
reagents (GE Healthcare Bio-Sciences). 
1.2.7. Patch clamp 
The patch clamp technique was developed by Neher and Sakmann in the late ‘70s. This 
technique revolutionized the field of physiology and biophysics by allowing the direct 
study of ion channel function. In this technique a small heat-polished glass pipette is 
pressed against the cell membrane where the ion channels are embedded and forms an 
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electrical seal with a resistance of ~1-2 GΩ that allow the measurement of ionic current 
(Hamill et al., 1981). An electrode (a silver wire coated with AgCl), located inside the 
glass pipette and connected to the circuitry, converts the ionic current into electrical 
current. This configuration is defined as cell-attached (Figure 10 A). After achieving a 
gigaseal there are several configurations that can be used. Whole cell configuration, in 
which the membrane patch is disrupted and the the pipette solution is continuous with 
the cytoplasmic mileu allowing for recordings from the ion channels present in the 
whole cell membrane (Figure 10 B). 
 
Alternatively, it is possible to rapidly withdrawed the pipette from cell-attached 
configuration to achieve the inside-out configuration in which one has access to the 
cytoplasmic face of the channels and allowing then current recordings in known 
intracellular solutions (Figure 10 C). If this maneuver is made in whole cell mode, the 
 
 
Figura 10. Patch clamp configurations. A high resistance seal called a “gigaseal” 
is formed when negative pressure is applied after the pipette is in contact with the 
cell membrane (A). B) In whole-cell mode, the cell membrane is ruptured by 
applying additional negative pressure thereby allowing one access to the interior of 
the cell and record a sum of all currents crossing the entire cell membrane. From 
cell-attached mode, one can retract the pipette to detach a portion of the membrane 
from the rest of the cell to enter the “inside-out” excised patch mode (C). D) 
Alternatively, from whole-cell mode, one can retract the pipette to form a vesicle at 




cell membrane will reseal upon itself to form a small vesicle at the pipette tip, called 
outside-out excised patch, in which the extracellular side of the channels can be 
manipulated (Figure 10 D). Another configuration is perforated patch, where the pipette 
contains specific antibiotics (such as gramicidin, anphotericin B or nystatin) that can 
inserted in the membraneof the cell in order to provide electrical access to the cell 
interior preserving the cytoplasm content (Figure 11). 
 
Patch clamp experiments: The patch electrodes (GB150F-8P with filament, Science 
Products) were pulled from hard borosilicate glass on a Brown-Flaming P-87 puller 
(Sutter Instruments, Novato, CA.) and fire polished to a tip diameter of 1-1.5 µm and an 
electrical resistance of 4-5 MΩ. The cells were voltage-clamped using an Axopatch 200 
B amplifier (Molecular Devices) in the perforated patch configuration or whole cell 
configuration. Ionic currents were digitized at 5 kHz and filtered at 1 kHz. Patch-clamp 
electrophysiology in perforated-patch experiments, the bath solution contained (in mM): 
  
Figure 11. Comparing the conventional whole cell patch-clamp configuration (left) 
and the perforated patch technique (right). In perforated patch, the electrical access 
to the cell is achieved taking advantage of the pore forming ability of certain 
antibiotics (such as gramicidin), the main advantage of this configuration is the 
preservation of the intracellular content. 
 
Gramic idin    
Gram icidin  pore    
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130 NMDG-Cl; 1.8 CaCl2; 2 MgCl2; 10 HEPES; 10 Glucose; 5 TEACl; pH 7.4 and the 
electrode solution contained (in mM): 145 KCl; 10 HEPES; 1 MgCl2; pH 7.25. The 
antibiotic Gramicidin (Sigma-Aldrich) was added to the pipette solution (2.5 µg/ml). 
Gramicidin is capable to insert into plasma membranes and form pores permeable only 
to monovalent cations, allowing to gain electrical access to the cell as well as preserve 
the [Cl-]i and the cytoplasm content. For whole cell experiments, the bath solution 
contained (in mM): 130 NaCl; 1.8 CaCl2; 2 MgCl2; 10 HEPES; 10 Glucose; 1 BaCl2; 
pH 7.4, while the pipette solution contained (in mM): 135 KCl; 5 TEACl; 10 HEPES; 
0.5 MgCl2; 0.1 CaCl2; 1 EGTA; pH 7.2. The voltage protocol consisted of 800 ms 
pulses from -100/-60 mV to +80/+60 mV (20 mV voltage steps); the holding potential 
was set according to the resting potential of the cell (between -40 and -80 mV). Cell 
capacitances were measured in whole cell configuration using a two-step protocol (from 
0 mV to -5 mV and from 0 mV to -10 mV), and resulting capacitances were used to 
calculate current densities. For time-course experiments, we held the voltage at -20 mV, 
measuring the current at the end of 800 ms voltage step from -40 to +60 mV membrane 
potential every 5 seconds. 
CLIC1-mediated Cl- currents were isolated from the other ionic currents in the cells by 
perfusing a specific inhibitor (Indanyloxyacetic acid 94, IAA94 100 μM) dissolved in 
the bath solution. Other Cl- currents were isolated using the aspecific inhibitor DIDS 
200 μM (Disodium 4,4′-diisothiocyanatostilbene-2,2′-disulfonate). In the experiment 
with metformin we isolate the metformin sensistive current (Imetformin) by perfusing 
10mM. 
Analysis: Offline analysis was performed using Clampfit 9.0 (Molecular Devices), 
OriginPro 8.5. IAA94-sensitive (IIAA94), DIDS-sensitive (IDIDS) and metformin-sensitive 
(Imetformin) currents were estimated by analytical subtraction of ionic currents after 
addition of either inhibitor from the total current (ITOT) of the cell at each membrane 
potential tested. Current/Voltage relationships (or I/V curves) were constructed by 
plotting the averaged ionic current data points in the last 100 ms of the pulse against the 
corresponding membrane potential. IAA94-sensitive/DIDS-sensitive/Metformin-
sensitive currents were normalized to the total ionic current of the cell (IIAA94/ITOT and 
IDIDS/ITOT, IMetformin/ITOT respectively); IIAA94/ITOT%, IDIDS/ITOT% IMetformin/ITOT% and 
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from the same cell types were averaged and plotted against the membrane potential. For 
the dose response Metformin-sensitive currents were normalized to maximum CLIC1 
current isolated using IAA94 (IIAA94 max) of the cell. Error bars are the standard error of 





My thesis is part of a larger study aimed at understand the role of CLIC1 protein in 
cancer stem cells (CSC) from human glioblastoma. The goal is to comprehend the 
functional role of CLIC1 ion channel in the proliferation of the CSCs in order to 
possibly develop new therapeutic strategies. 
This project has been developed in collaboration with Dr. Pelicci laboratory at the 
European Institute of Oncology of Milan (IEO) and in Dr. Florio laboratory at the 
Center of Excellence for Biomedical Research of the University of Genoa (CEBR). 
1.3.1. CLIC1 is overexpressed in glioblastoma cancer stem cell and it 
mainly localizes at the plasmamembrane  
In order to assess the role of CLIC1 in glioblastoma, our collaborators in Dr Pelicci 
laboratory established primary cultures of cancer stem cell (CSC) isolated from 
different human glioblastomas (hGBM). The cells isolated from the tumor, were grown 
in a stem-cell-permissive medium as describe previously by Vescovi and colleagues 
(Vescovi et al., 2006). 
 
 
Figure 12. CLIC1 is overexpressed in human glioblastoma (hGBM) CSCs. 
CLIC1 expression level validates by quantitative reverse-transcription polymerase 
chain (qRT-PCR) in normal brain and in different patient-derived GBM 
neurospheres. (n=3 each, error bars represent 95% confidence interval). 
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Using RT-PCR they compared CLIC1 mRNA expression in different patient derived-
glioblastoma neurospheres (Figure 12). CLIC1 expression was clearly more abundant in 
cancer stem cell by ~15-20 fold increase as compared to human normal progenitor cells 
(NPC). 
Since CLIC1 is a metamorphic protein able to fold in at least two conformations (one as 
a soluble protein in the cytoplasm, the other as a membrane protein to form ion 
channels), we sought to understand whether the increase in CLIC1 mRNA was related 
to an increase in CLIC1 mediated current. To address this question, we took advantage 
of the patch clamp, a very powerful technique used to measure ionic conductances in 
single cells. Specifically, we used the variant of whole-cell patch-clamp recording, 
called perforated patch clamp that was developed to overcome the dialysis of 
cytoplasmic constituents that occurs with traditional whole cell. 
 
Figure 13. CLIC1-mediated current is more represented in CSCs. Rapresentative 
ionic current traces from perforated patches of neuronal stem cells (NSCs) (A) and 
glioblastoma cancer stem cells (CSCs) (B). The voltage protocol is shown above the 
traces. By analytical subtraction of the ionic current after 100 µM IAA94 addition 
from the total current of the cell, we obtained the IAA94-sensitive current (C,D). E-
F) show I-V relationships for the corresponding experiments in NSC and CSC, 
respectively. 































The electrode solution contains antibiotics which diffuse and form small pores in the 
membrane, providing electrical access to the cell cytoplasm. In the experiments 
presented here, we used gramicidin, which forms pores permeable only to monovalent 
cations. After gigaseal formation, the gramicidin inserted into the plasmamembrane 
within few minutes and this was ascertained by monitoring the capacitive current 
increase and the resting potential stabilization. The resting potential could vary between 
-30 mV and -80 mV and the holding potential of each experiment was set according to 
the resting potential of that specific cell. During the experiment we sequentially 
perfused bath solution and 100 μM IAA94 (CLIC1 inhibitor) on the cell and ionic 
currents were recorded at different imposed membrane potentials. By analytical 
subtraction, IAA94-sensitive currents were isolated from the total current of the cell 
(Itot). Since the absolute values of these currents were different from cell to cell, they 
were normalized to Itot obtaining the percentage of IAA94-sensitve current (% IIAA94) 
(also see methods for more details). 
In Figure 13, representative experiments are shown for murine neuronal stem cell 
(NSC) (Figure 13 A) and CSC (Figure 13 B). The Current/Voltage relationships showed 
the total current and IAA94-sensitive current relative to the experiments presented in A 
and B (Figure 13 E and F). Averaging all the experiments performed at each membrane 
potential, we found that CLIC1-mediated current was more represented in tumoral cells. 
For example at 20 mV % IIAA94 was 32.38%  7.7% (n = 5) in CSC and 13.09%  
4.39% (n = 5) in NSC (Figure 14 A).  
In addition, to quantify the protein content we performed western blot analysis using 
neurospheres lysate fractions obtained from CSC and NSC. By probing the lysate 
fractions with antibodies anti-CLIC1, we found that CLIC1 protein expression was 
increased in the plasma membrane of CSC compare to normal counterpart (Figure 14 
B). 
Taken together, these results suggest that the increase in CLIC1 mRNA level in CSC 





1.3.2. CLIC1 silencing impairs cell proliferation in glioblastoma 
neurospheres 
In order to study the functional role of CLIC1 in glioblastoma CSCs, the strategy was to 
reduce the expression of the total protein using RNA interference (RNAi) technique. A 
lentiviral vector encoding for the shRNA (short hairpin RNA) against human CLIC1 
(siCLIC1) or against the firefly luciferase (siLUC) for control, were engineered and 
trasduced into CSCs. To verify the extent of CLIC1 silencing in CSCs isolated from a 
patient (hGBMR#), a western blot was performed on both the infected cells and the 
control cells (no infection). By probing the blot with antibodies anti-CLIC1 and anti-
Vinculin, we found that CLIC1 protein expression was reduced by ~50 % in siCLIC1 
infected CSCs (Figure 15 A). 
 
Figure 14. Enrichment in the plasma membrane fraction of CLIC1 protein in 
glioblastoma CSCs. A) Averaged ratio of IAA94-sensitive currents over the total 
current of the same cell are plotted against membrane potential. Note that IAA94-
sensitive currents are more represented in CSCs (purple) compared to NSCs 
(orange). Error bars are SEM B) Western blotting analysis of CLIC1 expression 
level in the plasma membrane (PM) and cytoplasm-containing fractions from murine 




The self renew ability of CLIC1-silenced and control cell was assessed in vitro, using 
the methylcellulose assay. This technique consists in plating single cell in a semisolid 
medium and count the colonies after 15 days in culture. The clonogenicity was 
calculated as the percentage of the total number of seeded cells. The first observation 
 
Figure 15. CLIC1 silencing reduces clonogenicity and proliferation of 
glioblastoma (GBM) stem/progenitor cells. A) Western blot analysis was 
performed on whole lysates from siLUC, siCLIC1 and not-infected cells and probed 
with anti-CLIC1 and anti-Vinculin antibodies. B) Representative microphotographs 
of control (siLUC) and CLIC1-silenced (siCLIC1) neurospheres formed in 
methilcellulosecontaining medium after 15 days in culture. Scale bar = 300 μm. C) 
Neurosphere formation assay. The clonogenic capacity of control (siLUC) and 
CLIC1-silenced (siCLIC1) cells was evaluated by plating cells in methylcellulose- 
containing medium. After 15 days, each plate was examined under a light 
microscope, and the total number of neurospheres was determined. D) Quantification 
of the maximal diameters of control (siLUC) and CLIC1-silenced (siCLIC1) 
neurospheres from GBM patient 7 (hGBM#7). Ten neurospheres for each sample 
were analyzed. E) Quantification of hGBM#7 neurosphere cell number. Ten 




was that the silencing of CLIC1 caused an evident decrease in the ability of generating 
colonies as shown by microphotographs in Figure 15 B. Accordingly, the clonogenicity 
for CLIC1-silenced CSC (white bar) was 3.83  1.75% and 11.63  5.23 % for the 
control (black bar) (Figure 15 C). This observation reflected a decrease in the sphere 
size (siCLIC1 264.0  13.50 µm and 502.5 56.85 µm for siLUC) and a lower 
neurosphere cellular content (siCLIC1 483.33  85.68 cells and to 830  119.22 cells in 
siLUC) for CLIC1-silenced CSCs (Figure 15 D and E). 
Taken together, these data show that CLIC1 is required for proliferation of CSCs, 
therefore in the cell propagation in GBM neurospheres. 
 
1.3.3. siRNA completely abolishes CLIC1-mediated currents in 
glioblastoma cancer stem cells 
Since glioblastomas are highly proliferating tumors and CLIC1 is involved in the 
proliferation, we asked whether the reduction in CLIC1 protein level obtain with 
shRNA was associated with the modification in the CLIC1 mediated current.  
To address this question we carried out perforated patch clamp experiments in CLIC1-
silenced human CSCs (siCLIC1) and control CSCs (siLUC). During the experiments I 
perfused bath solution, 100 μM IAA94 (CLIC1 inhibitor) and 100 μM IAA94 + 200 μM 
DIDS (Cl- channels inhibitor that does not affect CLIC1 current) and the ionic currents 
were recorded at different imposed membrane potentials in each condition. By 
analytical subtraction IAA94- and DIDS-sensitive currents were isolated from the total 
current of the cell (Itot) and they were normalized to Itot obtaining the percentage of 





Figure 16. siRNA abolishes CLIC1 currents in CSCs. A) Rapresentative ionic 
current traces from perforated patches of CSCs from hGBM#7 tumors siLuc and 
siCLIC1 cells. The voltage protocol is shown above the traces. By analytical 
subtraction of the ionic current after 100 µM IAA94 addition from the total current 
of the cell, we obtained the IAA94-sensitive current (IIAA94); the DIDS-sensitive 
current (IDIDS) is calculated by subtracting the current after 200 µM DIDS addition 
from the current after IAA94 effect. B) shows I/V relationships for the 
corresponding experiments in A. CLIC1-silenced cells display a complete 































The IAA94-sensitive current was absent in the siCLIC1 cells (Figure 16 A, right 
pannel) unlike DIDS-sensitive currents, which were recorded from all cell groups. The 
Current/Voltage relationships showed the total current, IAA94-sensitive current and 
DIDS-sensitive current relative to the experiments presented in Figure 16 A. Averaging 
all the experiments performed at each membrane potential, I found that, for example, at 
20 mV % IIAA94 28.05%  3.97% (n = 7) and 2.38%  0.91% (n = 5) in siLUC and 
siCLIC1 cells respectively; while IDIDS was 21.09%  5.65% (n = 4) in siLUC cells and 
28.45%  13.05% (n = 3) in siCLIC1 cells (Figure 17 A and B). 
 
These results demonstrate that siRNA against CLIC1 completely abolished CLIC1 ion 
channel activity, while the DIDS-sensitive current were unaltered, indicating that the 
viral infection did not produce off target effect on other chloride conductances. These 
findings support the view that CLIC1 ion channel activity is relevant in the proliferation 
activity of CSCs. 
 
 
Figure 17. siRNA abolishes CLIC1 currents in CSCs. These plots report the 
averages of the ratio of IAA94-sensitive currents (A) and DIDS-sensitive currents 
(B) over the total current of the same cell, for experiments performed in hGBM#7 
glioblastomas CSCs. IAA94-sensitive currents, but not DIDS-sensitive currents, are 































1.3.4. IAA94 and Metformin exert similar effects on CLIC1 
mediated current 
To target CLIC1 ion channel, the only effective drug so far identified is IAA94 which 
seems to be rather specific, but toxic. For this reason we sought non-toxic drugs that 
could interact with CLIC1 ion channel. Different epidemiological studies reported that 
Metformin, the most widely used antidiabetic drug in the world, is associated with 
reduced recurrence and favorable prognosis in several cancers (Kourelis and Siegel, 
2012; Ning et al., 2013). Furthermore Metformin directly inhibits cancer proliferation, 
preferentially acting on CSC (Sato et al., 2012; Wurth et al., 2013; Ning et al., 2013).  
Since CLIC1 is overexpressed in human glioblastoma and it is involved in proliferation 
of CSCs, we wanted to test whether Metformin exerted its antiproliferative role acting 
on CLIC1 ion channel. 
We assessed a dose-response curve for Metformin in perforated patch experiment using 
a human glioblastoma cell line U87-MG (Ponten and Macintyre, 1968) (Figure 18). The 
cells were perfused with a single dose of Metformin, in order to isolate the Metformin 
sensitive current. The ratio between the Metformin sensitive current and total CLIC1 
maximum current (isolated using 100 μM IAA94) was then calculated for each cell and 
plotted against [Metformin] (Figure 18). The dose-response data points followed a 




Figure 18. Metformin dose response curve. The ratio between Metformin and 
IAA94 sensitive currents (+60 mV, 750 ms test potential) was used to calculate a 
Metformin EC50 of 2.1 ± 0.4 mM (mean ± s.e.m.) from a dose/response plot (n=4 
independent experiments for each concentration). 
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To test the specificity of Metformin (10 mM) for CLIC1, we compared the extent of 
block of this drug to the one of IAA94 (100 µM) by sequentially adding the two 
inhibitors with either this order or the opposite (Figure 19). In panel A of Figure 19, I 
perfused IAA94 and subsequently IAA94 + Metformin, whereas in B the order was: 
Metformin and Metformin + IAA94. By analytical subtraction, IAA94- and Metformi-
sensitive currents were isolated from the total current of the cell (Itot). These currents 
were normalized to Itot obtaining the percentage of IAA94-sensitive current (% IIAA94) 
and Metformin-sensitive current (% IMetformin). In both cases the first compound (IAA94 
in A or Metformin in B) decreased the whole cell current, but most importantly the 
addition of the second inhibitor (Metformin in A or IAA94 in B) did not produce further 
sensitive current in both cases (Figure 19). Averaging all the experiments performed at 
each membrane potential, we confirmed that % of inhibition due to the first inhibitor 
were similar: at 40 mV the % of current blocked by the first inhibitor IAA94 is 34.33% 
 6.69 % (n=5) and with Metformin is 33.23  4.52% (n=5, Figure 14 A and B). 
Furthermore the addition of the second inhibitor resulted in % of sensitive current 
essentially null (For example 20mV %IIAA94 was 0.77 %  1.27% and IMetformin 0.60%  
0.78% (n = 5, Figure 20 A and B). Interestingly, experimental data show that 
Metformin-mediated inhibition of CLIC1 is similar to IAA94 block, suggesting that 




Figure 19. Inhibition of CLIC1 current by Metformin or IAA94. Representative 
traces of Metformin- and IAA94-sensitive currents recorded in perforated patch 
configuration elicited by different 800ms voltage step (from -80 to 80mV). IAA94 
(100 μM) and Metformin (10mM) were perfused on the same cell in this (A) or in 
the reverse order (B). (C, D) show I/V relationships for the corresponding 
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1.3.5. CLIC1 involvement in Metformin antiproliferative effect in 
human glioblastoma 
Considering that metformin displays antiproliferative activity mainly acting on CSC 
(not in differentiated cells) (Wurth et al., 2013) and that CLIC1 it has been 
demonstrated important for CSC proliferation, we asked whether the Metformin 
antiproliferative activity is in part mediated by CLIC1. 
The CSCs were grown as floating neurospheres in stem cell-permissive medium (No 
FBS) or in FBS-medium (without growth factors) to induce the differentiation (Figure 
21 A). Using western blot analysis, we verified the extent of the differentiation process, 
by assessing the expression level of an astrocytic marker, the glial fibrillary acidic 
protein (GFAP), in differentiated cells and CSCs (Figure 21 B). This analysis revealed 
that the differentiated cells are enriched in GFAP content compared to CSCs, as 
expected for glial cells (Figure 21 B). By probing the blot with antibodies anti-CLIC1 
and α-tubulin, we found that CLIC1 expression was significantly reduced in 
differentiated cells (Figure 21 B) suggesting that CLIC1 was highly expressed in CSCs 
but their protein level dropped down after differentiation. Has the differentiation 
process changed CLIC1 ion channel expression? To address this question, we 
Figure 20. CLIC1 mediated current is equally sensitive to Metformin and 
IAA94. These plots report the averages of experiments performed in U87-MG in 
which we perfused IAA94 and later Metformin in this (panel A) or in reverted order 
(B). It is reported the ratio of IAA94-sensitive current (red square) or Metformin-
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performed perforated patch experiments measuring Metformin-sensitive current in 
CSCs and differentiated cells using Metformin (Figure 22 A). During the experiments 
we noticed that the differentiation process considerably changed the morphology of the 
cells, from spherical (CSCs) to fully spread (differentiated cells) (Figure 21 A). How is 
this affecting current density? 
 
One disadvantage of perforated patch is that the evaluation of cell capacitance remains 
uncertain, because of the low accessibility to the cytoplasm when the antibiotic 
perforates the membrane. To overcome this issue, we measured the membrane 
capacitance in the two groups of cells using the whole-cell configuration. The averaged 
membrane capacitance was statistically different between two groups of cells: 6.52  
0.92 pF in CSCs and 69.56  6.46 pF in differentiated cells (Figure 22 B). We used 
these measurements to normalize the Metformin-sensitive CLIC1 current, I observed 
 
Figure 21. CLIC1 expression is reduced in differentiated cells. A) Representation 
of the differentiation process. By shifting CSCs from growth factor-supplemented 
(top) to growth factor-free and FBS-containing medium (medium/bottom) we 
obtained a stable culture of differentiated cells. B) Representative expression of 
CLIC1 and GFAP in GBM1 CSC-enriched and differentiated cell cultures. CLIC1 




that for example at +20mV the current density was 1.57  0.51 pA/pF for CSCs (n=6) 
and 0.51  0.15 pA/pF for differentiated cells (n = 5) (Figure 22 C). Interestingly, the 
relative abundance of CLIC1-mediated current in CSCs was about three-fold bigger 
than in differentiated cells. 
 
1.3.6. Point mutation in CLIC1 Arginine 29, impairs the Metformin 
inhibition 
Since Metformin blocks CLIC1 mediated current, we asked in which portion of CLIC1 
ion channel Metformin can effectively bind. CLIC1 has a single putative 
transmembrane domain composed by 22 amino acids, including two charged residues: 
arginine 29 (Arg29) and lysine 37 (Lys37). In particular the arginine 29 is likely to be 
near the mouth of the pore and it has been recently demonstrated to be important for the 
Figure 22. Differentated cells have less Metformin-sensitive current compared to 
CSCs. A) Comparison of Metformin-sensitive membrane current recorded in 
perforated patch experiments, in CSC (left) and differentiated (right) from GBM1. B-
C) Cell capacitance measurements (***p<0.001, t-test) (B), were used to obtain 
membrane current densities in CSC (square) and differentiated cells (circle) (C) (n=5, 
mean ± s.e.m. from 5 independent experiments) 
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channel open probability (Averaimo et al., 2013). Taking advantage of computational 
modeling and the available CLIC1 crystal structure, our collaborator predicted that the 
arginine 29 may form part of the Metfomin binding site. 
To test this hypothesis we used CHO cells stably transfected with two constructs: 
CLIC1 WT and CLIC1 R29A, where Arg29 was substituted with an alanine.  
 
We performed time course experiments in perforated patch configuration, pulsing the 
cells to +60 mV every 5 sec. After reaching the stability of the recording we 
subsequently perfused Metformin (10 mM) and IAA94 (100 μM) (Figure 23 A and B). 
In CHO transfected with CLIC1 WT the perfusion of Metformin completely blocked 
CLIC1-mediated current and therefore IAA94 did not further decrease the membrane 
current (Figure 23 A). This result confirmed again that Metformin and IAA94 have 
CLIC1 as a common target. In CHO cells transfected with CLIC1 R29A, Metformin 
indeed partially blocked the membrane current and the addition of IAA94 was 
necessary for a complete block of CLIC1-mediated current. Quantifying the Metformin-
sensitive current compared to the CLIC1 total current (IMetformin/IIAA94max) we estimated 
the effect of Metformin in CHO transfected with WT, R29A or native cells (not 
transfected) (Figure 24). The ratio in native and CLIC1 WT cells were similar (0.83  
 
Figure 23. Arginin 29 is important in the CLIC1 block mediated by Metformin. 
A) Whole-cell current time-course of CHO cells transfected with CLIC1-wt. 
Metformin (10mM) inhibited membrane current, which was not further decreased by 
IAA94 (100μM). B) Time-course using CHO cells transfected with CLIC1 R29A. 
This representative experiment showed that Metformin achieved only a partial block 




0.06 and 0.83  0.03 respectively) underlying again the specificity of Metformin on 
CLIC1.  
 
Furthermore IMetformin/IIAA94max in R29A was 0.54  0.06. These results suggested that 
the arginine 29 is a critical amino acid that mediates the action of Metformin. 
  
 
Figure 24. Arginin 29 is important in the CLIC1 block mediated by Metformin. 
Box-plot quantifying metformin insensitive portion of IAA94-sensitive current. 
Ratio between metformin (10mM) and IAA94 (100µM) is reported for native CHO 
cells, cells transfected  with CLIC1-wt (n=8) and CLIC1-R29A (n=9).Only the trials 
with CLIC1-R29A produced a value significantly different from the others (**p 




This thesis points out the pivotal role of the transmembrane fraction of CLIC1 chloride 
channel in the proliferation of human glioblastoma cancer stem cells (CSCs), the pool 
of cells that appears to be associated to invasiveness and recurrence of the tumor after 
initial treatment (Stiles and Rowitch, 2008; Bao et al., 2006). Thus, more effective 
interventions to contain or eradicate this disease can be achieved by pharmacologically 
targeting CLIC1 using an antidiabetic drug, Metfomin.  
Glioblastomas are the most common and aggressive primary brain tumors. Despite 
different treatment modalities, overall results have remained unchanged over the last 
years suggesting that standard therapies are actually ineffective in the eradication of the 
glioblastoma cancer stem cells. Recently it has been demonstrated the overexpression of 
CLIC1 in several tumors (Petrova et al., 2008; Chen et al., 2007; Tang et al., 2012; Wei 
et al., 2015), including high grade glioblastoma (Wang et al., 2012). Not only CLIC1 is 
overexpressed in glioblastoma, but most importantly the expression of this protein 
greatly correlates with the glioblastoma prognosis, as previously shown by Wang and 
collegues and in our recent paper (Wang et al., 2012; Setti et al., 2013). These 
discoveries suggest that CLIC1 is an actor in the cancer progression and most 
importantly that this protein could actually be a potential prognostic marker in 
monitoring glioblastoma progression. 
What is the role of CLIC1 in favoring tumor progression?  
By silencing CLIC1 in CSCs from human glioblastoma biopsies, we established that 
CLIC1 is extremely important for in vitro CSC proliferation (Figure 15). This 
interesting observation was corroborated by in vivo experiments in which by orthotopic 
injection of CLIC1 silenced CSC (siCLIC1) in the brain of immunocompromised mice, 
we demonstrate the impairment of tumorigenic potential of these cells as reported in our 
recent paper (Setti et al., 2013). Being CLIC1 a dimorphic protein, we ask whether the 
proliferation impairment is mediated by the cytoplasmic protein fraction or by the 
transmembrane one. Interestingly, electrophysiological recordings from siCLIC1 cells 
show that the CLIC1-mediated current is completely abolished (Figures 16 and 17). 
Furthermore, the CLIC1 ion channel, and not the cytoplasmic one, is the discriminating 
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factor between CSC vs normal stem cell or differentiated cell (Figures 13, 14 and 22). 
Thus, it is reasonable to think that the overexpression of CLIC1 and the localization at 
the plasma membrane confer a proliferative advantage to CSCs and therefore to the 
tumor mass development. This is actually in line with previous studies reporting the 
involvements of CLIC1 in cell proliferation (Valenzuela et al., 2000; Tung and 
Kitajewski, 2010). We know that the soluble form of CLIC1 has glutaredoxin-like 
enzymatic activity that may be important for protecting the intracellular environment 
against oxidation in physiological condition (Al Khamici et al., 2015). It is also likely 
that this activity regulates CLIC1 ion channel function, favoring the insertion of CLIC1 
in the membrane under oxidative cytoplasmic potential. Furthermore, in our recent 
paper (Gritti et al., 2014) we demonstrated that CLIC1 is relevant in the GBM cell cycle 
only when the protein translocates to the plasma-membrane to allow the G1-S transition 
of the cells. Since the progression of the cell cycle is due to rhythmic oxidative 
fluctuations (Menon et al., 2003; Menon and Goswami, 2007; Havens et al., 2006), it is 
reasonable to hypothesize that CLIC1 following the cytoplasmic oxidative oscillations 
relocates to the plasma membrane where it acts as chloride channel. We might 
hypothesize that the translocation of CLIC1: i) determines a flux of Cl- ions out of the 
cell, necessary in the volume rearrangements during the proliferation or migration (Mao 
et al., 2008; Pani et al., 2010) or ii) may support the function of NADPH-oxidase, an 
enzyme actives during oxidative conditions and thus in CSC, by balancing the excess of 
positive charges supporting the production of superoxide anions by the enzyme 
(Averaimo et al., 2010; Milton et al., 2008; Menon et al., 2003). We do not have a full 
explanation about the mechanism yet, and further experiments need to be done focusing 
on the difference of the role of CLIC1 in physiological condition in order to better 
understand what happen in the pathological condition. 
Overall these findings suggest CLIC1 as a novel pharmacological target in glioblastoma 
treatment due to its accessibility from outside the cell and transient appearance in the 
membrane relevant for CSCs proliferation. So far, the only effective CLIC1 channel 
blocker identified is IAA94 (Valenzuela et al., 2000). This compound acts as a pore 
blocker, interrupting the ion flux through the channel. IAA94 seems rather specific but 
highly toxic. Important in these context is to find and test other compounds that block 
CLIC1 current more specifically and that can be administer to patients. Recently, 
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several studies reported the in vitro and in vivo efficacy of metformin, the most widely 
used antidiabetic drug in the world, as antitumoral agent for several human tumors, 
including GBM (Wurth et al., 2013; Sato et al., 2012) showing its efficacy in reducing 
proliferation, survival, clonogenicity and in vivo tumorigenicity of CSCs subpopulation.  
These studies are really important because they contribute and accellerate the ongoing 
clinical trial (Kourelis and Siegel, 2012; Pernicova and Korbonits, 2014), but in most of 
the cases they did not unravel the mechanism by which metformin reduces tumor and 
why this compound is selective for CSCs. We propose CLIC1 to be the molecular target 
of metformin activity.  
Interestingly, we found that Metformin and IAA94 share the same target acting on 
CLIC1 ionic current in very similar manner (Figures 19 and 20). As reported in our 
recent paper (Gritti et al., 2014), Metformin exerts antiproliferative activity similar to 
IAA94 showing a higher specificity toward CSC in human glioblastoma compared to 
differentiated cells. To further validate these findings, we have compared the expression 
of CLIC1 ion channel in these two groups of cells.  
The differentiation process decreases CLIC1 protein expression (as verified by western 
blot) and the related current (Figures 21 and 22). Thus, the different activity and 
availability of CLIC1 as active chloride channel in CSCs and differentiated cells 
dictates the strict selectivity of metformin towards CSCs. In addition the selectivity of 
metformin for cancer cells is a rather unique characteristic for antitumoral drugs and it 
is also demonstrated by the absence of significant toxicity of metformin when 
chronically used in diabetic patients. 
Where does Metformin bind CLIC1? We demonstrate that Metformin interacts with 
CLIC1 from the external side of the membrane at the amino terminus of the channel, 
presumably near the side chain of Arg29 (Figures 23 and 24), which it has recently 
describe as responsible for destabilizing the closed state of the channel (Averaimo et al., 
2013). These data allowed us to build a theoretical model for Metformin action. Arg29 
is likely to be near the anion path proximal to the extracellular surface. As it destabilizes 
the closed state of the channel, it could interact with a polar portion of the channel via 




Using its double guanidinium group, Metformin may displace the side chain of Arg29 
from this polar pocket, stabilizing the closed state and possibly obstructing the channel 
pore displacing the large arginine side chain (Figure 25 B). Metformin can only access 
this polar site from the outside of the cell, as the binding site is near to the cell surface, 
given the position of Arg29 in the putative TM segment. In contrast, CLIC1- R29A, 
lacking Arg29 side chain, displays a more stable closed state, only opening at high 
membrane potential (Figure 25 C). The polar binding pocket (normally occupied by the 
guanidinium moiety of Arg29) is exposed and free to bind Metformin (Figure 25 D). 
However, Metformin binding has no effect on the electrophysiological properties of the 
 
Figure 25. Modelling of Metformin-CLIC1 interaction. Schematic representation 
showing a possible mechanism of Metformin’s inhibition of CLIC1 wt, while it has 
no effect on R29A mutant. A) In the closed state of CLIC1 wt, the side chain of 
Arg29 makes an interaction that destabilizes the closed state. This facilitates the 
opening of the channel near the chloride reversal potential. B) Metformin displaces 
the guanidinium moiety of Arg29, stabilizing the closed state. In addition, the 
displaced Arg29 side chain may obstruct the channel pore. C) In the R29A mutant, 
the closed state is stable near the chloride reversal potential, as there is no Arg29 side 
chain to make the destabilizing interaction as it is replaced by Ala29. D) Metformin 
is free to bind to the guanidinium site in R29A, as it is unoccupied. It has no effect 
on channel opening at high membrane potentials. 
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Arg29-lacking mutant, as there is no arginine side chain to displace to cause channel 
inhibition. 
In conclusion, the ability of Metformin to block CLIC1-mediated current suggests that 
its anti-proliferative activity in GBM CSCs is, at least partially, independent from other 
intracellular pathways. However, comparing the effects of Metformin and IAA94 
(CLIC1 inhibitor) some differences in efficacy and cell sensitivity are apparent in GBM 
cells. In our and other reports, Metformin antitumor effects occur at concentration in the 
millimolar range (1-50mM) (Gritti et al., 2014; Cufi et al., 2012; Hirsch et al., 2009; 
Martin-Castillo et al., 2010; Chen et al., 2012). We are aware of the fact that Metformin 
is not the ideal CLIC1 blocker due to the low affinity (EC50=2.1 ± 0.4 mM) (Figure 18), 
but on the other hand Metformin treatment has been demonstrated to have negligible 
side-effects in patient and it is not toxic to normal stem cells and differentiated cells 
(Kusne et al., 2014; Lee et al., 2014; Wurth et al., 2014; Wurth et al., 2013). 
Furthermore a recent study demonstrates that Metformin is able to cross the blood-brain 
barrier (Sato et al., 2012; Labuzek et al., 2010) and therefore represents a valuable 
therapeutic tool that can be considered in glioblastoma drug design. Based on the 
proposed Metformin binding site of CLIC1 ion channel, the future effort will be 
directed towards designing new pharmacological compounds inspired on IAA94 and 
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2.1.     Introduction 
2.1.1. Electro-Mechanical activity of the heart 
The heart is an electromechanical pump that requires to be electrically activated in order 
to contract. In the normal heart, action potentials are spontaneously generated by the 
pacemaker cells in the sinus node (SAN), propagate to the atria and via a specialized 
conduction system to the ventricles (Figure 1). A tight regulation of this electrical 
conducting system is critical for the synchronous contraction of both atria and ventricles 
in order for blood to be pumped efficiently to the lungs for oxygenation and to the body 
for delivery of oxygen and nutrients. At the cellular level, the depolarization of a 
cardiac cell (myocyte) activates an influx of calcium that triggers the contraction after 
an electromechanical delay of a few milliseconds (Bers, 2002; Ashikaga et al., 2007). In 
fact, during AP the plateau phase (Figure 2) is critical for the proper functioning of the 
cardiac tissue since allows sufficient time for Ca2+ to enter the cell, induces Ca2+ release 
from the sarcoplasmic reticulum (SR) (Figure 3). This massive increase in [Ca2+] 
engages the contraction machinery (actin and myosin filaments), and initiates 
contraction of the cardiac muscle, an event which ultimately pumps blood to the tissues 
in the body. Following the contraction (systole) the muscle fibers must relax (diastole) 
to allow refilling of the blood of the heart for the next beat. The intracellular Ca2+ must 
be recycled back into the SR through the sarco-endoplasmic reticulum Ca2+-ATPase 
pump (SERCA) pump or extruded back into the extracellular medium via Na/Ca-
exchanger (NCX) (Figure 3). The tissue must repolarize before the next oncoming AP, 
when the process begins again (Bers, 2002). This cycle of excitation, contraction and 





2.1.2. The Ventricular action potential 
The cardiac action potential (AP) is a rapid rising and falling of the electrical potential 
across a membrane of a myocyte. The shape of the AP is dependent on the overall 
interactions between the various inward and outward ionic conductances over the course 
of the AP (Figure 2) (Ravens and Cerbai, 2008). The action potential shape and duration 
differs in various parts of the heart mainly because of different type and density of ion 
channels and transporters expressed. In a ventricular myocyte the AP typically displays 
5 phases ("phase 0" to "phase 4"). During phase "0", a massive flux of Na+ ions 
(generated by the activation of voltage-gated Na+ channels, VGSC) drives the 
membrane potential (Vm) from its resting level (~-80 mV) towards Na+ electro-
chemical equilibrium potential (ENa) forming the upstroke of the AP (~40 mV, phase 0) 
(Figure 2). Following this rapid membrane depolarization, sodium channels begin to 
inactivate, causing a reduction of Na+ conductance. The positive Vm activates a 
transient outward K+ current (Ito) that produces a partial repolarization (phase 1) 
interrupted by a plateau phase (phase 2) where a substantial Ca2+ influx produced by the 
activation of L-type Ca2+ current (ICa,L) is counterbalanced by a K+ efflux through 
 
.  
Figure 1. The Conduction System of the Heart. The natural rhythm of the heart is 
dictated by the pacemaker cells within the Sinoatrial (SA) node. The electrical 
impulse travels from the SA node, through the atrial tissue to the atrio-ventricular 




Figure 2. Inward and outward currents that 
shape the ventricular action potential. The 
top panel shows a ventricular action potential 
(AP) and the different phases that 
characterize the AP. Inward currents are 
mainly conducted by Na2+ and Ca2+ 
channels; outward currents are mainly 
conducted by various potassium channels. 
Phase 0 shows a rapid depolarization; phase 
1 shows a rapid early repolarization; phase 2 
shows a slow ‘plateau’ of repolarization; 
phase 3 shows a rapid late repolarization; 
and phase 4 shows resting potential. Adapted 
from (Boukens et al., 2009) 
voltage gated delayed rectifier channels (IKr and IKs). This plateau phase (~300 ms) is 
essential for the prevention of electrical re-excitation and tetanic contraction in the 
heart, which could inhibit relaxation 
needed for the filling of blood prior 
to ejection (Bers, 2002). The influx 
of Ca2+ through L-type Ca2+ channels 
(LTCC) during this plateau phase has 
implications. First, the Ca2+ entry 
induces Ca2+ release from the SR by 
activating ryanodine receptors 
(RyRs), a phenomenon known as 
Calcium-Induced Calcium-Release 
(CICR) (Figure 3) (Bers, 2002; Bers 
and Guo, 2005). This massive 
increase in Ca2+ concentration in the 
myocyte (from 0.1 μM up to 1μM), 
engages the contraction machinery as 
the actin and myosin filaments 
transduce chemical energy into 
mechanical force (Bers, 2002). 
Moreover, Ca2+ entry binds to 
calmodulin (CaM) which is directly 
associated with the L-type Ca2+ 
channel, and initiates Ca2+-dependent 
inactivation (CDI) (Peterson et al., 1999). Eventually, a decay in the Ca2+ current due to 
CDI and voltage-dependent inactivation (VDI) of the LTCCs allows K+ conductances to 





During this phase, the surplus intracellular Ca2+ is pumped back to either the 
extracellular medium or the sarcoplasmic reticulum (SR) via the Na/Ca-exchanger 
(NCX) or the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), respectively (Figure 
3). This resets the cell to a diastolic state (phase 4), during which the myocyte relaxes 
and is ready for the next heartbeat. 
 
2.1.3. Triggers of ventricular arrhythmias 
Sudden cardiac death (SCD) is one of the major leading causes of death in the United 
States, accounting for about more than 300,000 deaths every year. SCD is often caused 
by cardiac arrhythmias that lead to the heart being unable to pump blood efficiently to 
the body. The most dangerous cardiac arrhythmias arise in ventricular tissue and include 
ventricular tachycardia (VT) and ventricular fibrillation (VF) (John et al., 2012). 
Ventricular tachycardia can often be diagnosed and treated but ventricular fibrillation 
 
.  
Figure 3. Scheme of calcium cycle in a ventricular myocyte. Ca2+ enters via ICa (L-
type calcium channel) and Na/Ca-exchanger (NCX). The influx of Ca2+ controls the 
sarcoplasmic (SR) Ca2+ release via ryanodine receptor (RyR). The massive increase 
of [Ca2+] controls engages the contraction machinery (actin-myosin) that determines 
the contraction.  The main entryway of Ca2+ from the extracellular medium is the L-
type Ca2+ channels shown in orange. Ca2+ is then mainly removed from the 
cytoplasm by SR Ca-ATPase (SERCA) (modulated by phospholamban, PLB) and by 
the Na/Ca-exchanger (NCX) and mitochondrial uniporter. ATP is Na/K ATPase, 
PLB is phospholamban, SR, sarcoplasmic reticulum. The graphs in the box show, in 
black, a ventricular myocyte’s AP; in blue the intracellular [Ca2+] during the course 
of the AP; in red, the contraction of the cardiac muscle (Bers, 2002). 
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almost always results in cardiac arrest and death if not terminated quickly. The cardiac 
excitation that occurs for every single beat can be viewed as a electrical wave that 
emerge focally in the SAN and spreads out through the whole heart (the cardiac action 
potential). If this wave of depolarization during the propagation brakes at one point 
originates two new broken end that become the locus of potential reentrant waves 
(spiral waves) (Weiss et al., 2000; Qu and Weiss, 2015). Thus, if this reentrant waves 
propagate in the heart tissue and collide with some anatomical obstacle, they create an 
reentrant circuit which represent an ectopic focus that rapidly and repetitively activate 
the ventricles. This produces an activity that contrasts the sinus rhythm and determined 
an abnormal rapid heartbeat. This situation is called ventricular fibrillation (VT). 
Sometimes the heart can reset this condition but in a more dangerous situation the VT 
can degenerate in a condition called ventricular fibrillation (VF). 
In fact sometime the reentrant wave presents in VT collides and develop wavebreaks 
that generate multiple reentrant waves characterized by multiple wavelets. 
 
In VF the ventricle are activated in a rapid and asynchronous way (The ventricles 
"fibrillate" rather than beat) that results in a disordered activity in which the heart 
cannot pump blood, causing cardiac arrest (Weiss et al., 2000; John et al., 2012). 
Cellular triggers of VT and VF are abnormal depolarization of the AP, called early 
afterdepolarizations (EADs) if they occur during systole or delayed afterdepolarizations 
 
Figure 4. Early Afterdepolarizations and Delayed Afterdepolarizations. Early 
afterdepolarzation (EAD) are single or multiple reversal of repolarization occurring 
in phase 2-3 of the cardiac action potential. A delayed afterdepolarization (DAD) 
occurs after repolarization of the AP is complete. Since Ca2+ channels cannot be 
activated at hyperpolarized membrane potentials during diastole, the cellular 
mechanisms for DADs involve INCX (Adapted from (Hoekstra et al., 2012). 
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(DADs) if they occur during diastole (Cranefield, 1977; Qu and Weiss, 2015) (Figure 
4). Although both EADs and DADs are considered highly arrhythmogenic, the 
underlying mechanism for each is still an open area of investigation. 
 
2.1.4. Early afterdepolarizations 
Early afterdepolarizations (EADs) are secondary voltage depolarizations occurring 
during the repolarization of the cardiac AP (phase 2 or 3) that tend to emerge at low 
pacing rate and hence are associated with bradycardic arrhythmias (Damiano and 
Rosen, 1984; January et al., 1988). 
EADs were first described by Cranefield and his colleagues in 1972 as they observed 
them in a Purkinje fibers of an intact cardiac tissue in canine (Cranefield et al., 1972). 
EADs were subsequently described as a form of "triggered activity" in myocardium 
caused by the transition from a normal to a rapid and asynchronous electrical activity of 
the heart that can cause VT and VF (Cranefield and Aronson, 1974; Cranefield, 1977) 
(Figure 5).  
Formation of EADs is largely dependent upon the net ionic conductance governing the 
phase 2 and 3 of the action potential. In fact they are mainly due to either abnormally 
decreased outward currents, increased inward currents, or both, classically defined as 
reduced repolarization reserve (Qu et al., 2013). Therefore, it could be due to an 
increase in the inward ICa,L and/or a reduction in the outward K+ current that could alter 
the repolarization phase such that the net increase in inward current eventually reverses 
the repolarization of the membrane potential (Weiss et al., 2010). Marban and 
colleagues demonstrated that an increase in extracellular Ca2+ augmented EADs 
occurrence, while blocking SR Ca2+ release with ryanodine or chelating intracellular 
Ca2+ maintained EADs in ferret ventricular tissue (Marban et al., 1986). Furthermore, 
they also showed that EADs were directly connected with the increase in the opening of 
Ca2+ channels by applying Bay K8644, a Ca2+ channel agonist and that EADs were 




The relevance of L-type calcium channel (LTCC) in the EADs formation was further 
studied by January and colleagues. Their findings suggested that EADs induction was 
dependent on both time and voltage-dependent mechanisms. In fact they observed that 
the voltages where EADs were induced, overlapped with the voltages where recovery 
from inactivation of the LTCCs occured (January and Riddle, 1989). January and 
Riddle subsequently tested their hypothesis that reactivation of LTCCs contributes to 
EAD formation by demonstrating that the voltage dependence of EADs mirrors the 
voltage-dependence and time-dependent recovery of LTCCs (January and Riddle, 
1989). Their experiments provided the first indication that L-type Ca2+ channel 
reopening during steady-state may allow the flux of an inward current due to the 
overlap of the activation and inactivation curves of LTCCs (Shorofsky and January, 
1992). Most EADs are initiated between -40 and 0 mV, corresponding to the range of 
membrane potentials where the steady-state activation and inactivation curves of ICa,L 
overlap, often referred to as the ‘window current’ region (shaded area in Figure 6) 
(January and Riddle, 1989; Antoons et al., 2007). Steady state curves of ICa,L show the 
voltage dependency of LTCC activation and inactivation over a range of membrane 
potentials. As the AP repolarizes into this voltage range of potential, a fraction of the L-
type Ca2+ channels not inactivated may be available for reactivation thus conducting 
inward Ca2+ current that induces the upstroke of the EADs. Another direct confirmation 
that EADs are related to ICa,L “window current” was assessed in our laboratory. In fact 
Madhvani and colleagues, established that EADs formation is highly dependent on the 
ICa,L biophysical properties and therefore on the ”window current” region (Madhvani et 
 
Figure 5. Early Afterdepolarizations trigger Ventricular Tachycardia and Ventricular 












al., 2011). Using the dynamic clamp technique they identified two parameters of the L-
type Ca2+ channel (LTCC) biophysical properties that potently suppress EADs 
occurrence. In particular subtle changes in the steady-state activation or inactivation 
properties of ICa,L (~5mV depolarizing shift of the V1/2 steady-state activation curve and 
~5mV hyperpolarizing shift of V1/2 the steady-state inactivation curve) potently suppress 
EADs formation. These results point out that a reduction of the ICa,L “window current” 
represents an effective maneuver to suppress EADs without blocking the early peak ICa,L 
required to maintain normal excitation-contraction coupling (Madhvani et al., 2011). 
 
EADs can be classified based on AP phase where they occur: during the plateau (called 
phase 2 EADs) or during repolarization (called phase 3 EADs). Depending on this 
classification, the proposed mechanism for EADs occurrence is different. Since phase 3 
EADs tend to arise at more hyperpolarized membrane potentials (below -40 mV) 
compared to phase 2 EADs, which occur at the plateau potential (between -10 mV and 
+20 mV), a number of laboratories have proposed that either the Na2+ “window current” 
or reverse-mode action of the Na-Ca exchanger could play a major role in phase 3 
EADs (Qu et al., 2013). The main reason is due to the fact that Ca2+ channels are not 
active below -40mV, and therefore unlikely to contribute to EAD formation. Modeling 
studies also corroborated the possibility of Na-Ca exchange current contributing to 
phase 3 EADs (INa-Ca) (Luo and Rudy, 1991; Luo and Rudy, 1994). 
 
In isolated myocytes there are several modalities to induce EADs. Different studies 
EADs were induced either by the presence of Cs+ to block K+ currents and delay 
repolarization or by directly altering the gating properties of LTCCs using an agonist 




Alternative methods being used are hypokalaemia, by lowering extracellular [K+] (from 
5.4 to 2.0-2.7 mM) to block IK1 and other potassium conductances (Sato et al., 2009) or 
oxidative stress, by exposure to 600 μM H2O2 (Xie et al., 2009). Several groups have 
demonstrated the EAD-genic effects of ROS. Hydrogen peroxide (H2O2), a potent 
biologically reactive ROS which can easily cross the plasma membrane, is directly 
produced in cardiac tissue upon reperfusion following ischemic injury (Slezak et al., 
1995; Brown et al., 1988a; Brown et al., 1988b). Furthermore many laboratories have 
provided evidence which suggests that H2O2 promote EADs by activating Ca2+–
calmodulin-dependent protein kinase II (CaMKII) (Xie et al., 2009), which alters late 
component of INa (Wagner et al., 2011; Wagner et al., 2006). In addition it has been 
reported the effect in other conductanced involved in shaping the AP included IKr, INCX 
and RyRs (Beresewicz and Horackova, 1991; Liu and Gutterman, 2002; Liu and 
O'Rourke, 2013). Madhvani and colleagues reported that H2O2 modified the ICa,L, 
slowing down the inactivation and shifting the peak of the current–voltage (I–V) 
relationship by −5 mV. Furthermore H2O2 changes the voltage dependence of the 
channel producing ∼−5 mV shift of the steady state half-activation potential (V1/2 act) 
 
Figure 6.  EAD formation occurs within the voltage range of “window current” 
region. A) the black curves show the steady-state activation and inactivation curves 
of ICa,L measured in rabbit ventricular myocytes in normal physiological Tyrode’s 
buffer solution. The red curves show the steady-state activation and inactivation 
curves of ICa,L after being exposed to 0.6 mM H2O2. The shaded areas are known as 
the “window current” region, which is the region where steady state activation and 
inactivation curves overlap. B) A rabbit ventricular cardiac AP with EADS recorded 
in 0.6 mM H2O2. The red shaded area reflect the “window current” regions of (A). 
This is showing that EADs often occurs within the “window current” region, 
between approximately -30 mV and +10 mV and that H2O2 increases the height of 








































and ∼+5 mV shift in the steady state half-inactivation potential (V1/2 inact). Effectively, 
H2O2 increased the height of the ICa,L “window current” region, changes which are 
expected to promote EAD formation increasing the number of ICa,L channel available to 
activate during the AP repolarization (Madhvani et al., 2011) as in Figure 6. 
 
2.1.5. Voltage-gated calcium channel 
Voltage-gated calcium channels are integral cell membrane proteins that mediate Ca2+ 
influx into the cell in response to membrane depolarization. The entered Ca2+ serves as 
an essential intracellular messenger that regulates a variety of cellular processes 
including muscle contraction, hormone secretion, neuronal transmission, and gene 
expression (Yang and Berggren, 2006; Flavell and Greenberg, 2008; Catterall, 2011; 
Catterall and Few, 2008). 
There are several Ca2+ currents that have been classified by their electrophysiological 
properties in L-, N-, P-, Q-, R-, and T-type (Catterall, 2011). 
 
2.1.6. L-type calcium channel (LTCC) 
In the ventricular myocytes, the predominant Ca2+ channel present is L-type channel 
(CaV1.2) and it is primarily localized in the T-tubules of skeletal and cardiac muscle 
cells (Wibo et al., 1991). LTCCs activate at depolarized voltage (-40mV) and have 
slower voltage-dependent inactivation that contributes to their long lasting conducting 
property (Tsien et al., 1988; Ono and Iijima, 2010). LTCCs are crucial in maintaining 
the time course of a cardiac AP, in providing the passageway of Ca2+ entry into the cell, 
and ultimately in excitation-contraction coupling of a cardiac myocyte. Ca2+ entering 
the cell during an AP triggers SR release of Ca2+ via Ca2+-induced Ca2+-release 
phenomenon (Bers, 2002). Although the inward current carried by LTCCs was 
characterized in the 1960s (Orkand and Niedergerke, 1964), the molecular identity of 
the cardiac L-type Ca2+ channel was established by Mikami and colleagues from rabbit 
hearts in the late 1980s (Mikami et al., 1989). The heteromultimeric LTCCs were first 
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cloned from rabbit skeletal muscle by Tanabe and colleagues in 1987 (Tanabe et al., 
1987).  
Topology 
LTCCs were first known as dihydropyridines receptors attributing to their sensitivity to 
dihydropyridines (DHP). They are multimeric protein complexes form by ion-
conducting pore α1 subunit and auxiliary subunits α2δ, β, and γ that involved in 




The LTCC α1 is encoded by a single gene (CACNA1) and has multiple splice variants, 
in the heart α1c (CaV1.2). The α1 subunit contains four homologous domains (I−IV), 
each comprising of six membrane-spanning segments (S1–S6) connected by 
intracellular loops. The S1–S4 segments from each domain form a voltage-sensing 
domain (VSD), whereas segments S5 and S6 contribute to the channel pore and contain 
the selectivity filter (Catterall, 2011). VSDs are structurally and functionally conserved 
modules capable of transducing a change in the cell membrane electrical potential. 
Recently it has been demonstrate that each of CaV1.2 VSDs possesses unique properties 
in the channel activation (Pantazis et al., 2014). The four domains are linked by 
intracellular loops which have residues that interact with β subunits via the α-interaction 
domain (AID) in the linker between I-II domain, while the intracellular C-terminal tail 
contains critical structural elements (pre-IQ, and IQ regions) necessary for 
Ca2+/calmodulin (CaM) binding site (Halling et al., 2006). In fact Ca2+/Calmodulin acts 
as an intrinsic calcium sensor modulating calcium-dependent inactivation (CDI) and 
calcium-dependent facilitation (CDF), both important for regulating the level of Ca2+ 
during cardiac AP (Catterall, 2011). Alseikhan et al. demonstrated the physiological 
importance of CaM as a Ca2+-sensor mediating CDI in LTCCs of cardiac myocytes 
using engineerined CaM (Alseikhan et al., 2002). This approach, in which the CaM was 
mutated at all four Ca2+-binding sites to abolish its Ca2+-sensitivity and heterogously 
expressed in adult rat cardiomyocytes, allowed the investigators to probe the 
physiological role of Ca2+-dependent regulation of LTCCs associated with CaM. Their 
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intriguing results show that in cells expressing the recombinant CaM, CDI was 
eliminated and only a monotonic decay remained resulting in very long APDs.  
In addition to CDI a slower, a purely voltage-dependent inactivation (VDI) process is 
present in CaV1.2. This control of the inactivation process is relevant for myocytes 
activity as it serves to limit the level of Ca2+ influx during prolonged depolarization and 
as a result, it regulates the toxic downstream effects of elevated intracellular Ca2+. 
 
Different mutation in CaV1.2 α1c subunit has been associated with the Timothy 
syndrome, the Brugada syndrome, and early repolarization syndrome, all diseases 
connected with an abnormal heart rhytm (Napolitano and Antzelevitch, 2011). 
 
Auxiliary subunits 
Three different auxiliary subunits, α2δ, β and γ, are known to modulate the activity of 
the α1 pore-forming subunit. α1 subunits normally interact with at least the α2δ and β 
subunits (Hosey et al., 1996). Singer and colleagues showed that expression of α1 
subunit alone contributes to functional LTCCs (Singer et al., 1991), while coexpression 
 
 
Figure 7. The L-type calcium channel (CaV1.2) is a multi-protein complex composed 
of α1C (pore-forming subunit) and distinct auxiliary subunits: α2δ, β and γ. The L-type 
Ca2+ channel polypeptide consists of four tandem domain (I-IV), each crossing the 
membrane six times (S1-S6). Helix S4 contains positively charged residues, which 
together with S1-S3, make up the voltage-sensing domain (VSD), whereas the loop 
between S5-S6 from each repeat contribute to the ion-selective pore. The intracellular 
loop between domains I and II contains the α-interaction domain (AID) which binds 
β subunits, while the C-terminal tail contains the calmodulin (CaM) binding IQ-




Figure 8. Cavβs modulate the biophysical properties 
of cardiac cardiac LTCC causing a shift in the steady-
state activation curve to more hyperpolarized 
membrane potential. Adapted from (Neely et al., 
1993). 
with α2δ and β subunits increases the current conductance by promoting trafficking of 
α1 subunit to the plasma membrane (Dolphin, 2012).  
α2δ There are four α2δ subunit isoforms (α2δ-1–α2δ-4). These proteins are the product 
of a single gene that is post-translationally cleaved into separate α2 and δ peptides held 
together by disulphide bonds (Dolphin, 2012). Most of α2δ subunit is extracellular, 
infact the large α2 protein is entirely extracellular and tethered to the plasma membrane 
via the δ subunit which has a short hydrophobic region that traverses the membrane 
(Davies et al., 2010; Catterall, 2011).  
β There are four distinct CaVβ subunits (β1–β4) encoded by four different genes, each 
subunit with multiple splice variants (Buraei and Yang, 2013). β subunits are cytosolic 
protein located near the plasma membrane. Cavβ was first purified as part of the 
complex of skeletal muscle 
voltage-gated Ca2+ channels 
and was cloned in 1989 
(Curtis and Catterall, 1984; 
Ruth et al., 1989). All 
CaVβs contain a conserved 
core comprised of src 
homology 3 (SH3) and 
guanylate-kinase like (GK) 
domains and three variable 
unstructured regions—N-
terminus, C-terminus, and a 
HOOK domain that 
separates SH3 and GK 
(Buraei and Yang, 2013). 
Different biochemical and 
electrophysiological have 
been demonstrated that in GK domain of CaVβs there is a conserve α1-binding pocket 
(ABP) region that binds with high (nM) affinity to a conserved 18-residue α1 interaction 
domain (AID) located in the intracellular loop between domain I–II of pore-forming α1 
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subunits (Pragnell et al., 1994). In 2004, three independent research groups reported the 
crystal structures of the Cavβ core region of β2a, β3 and β4, alone or in complex with the 
AID (Chen et al., 2004; Opatowsky et al., 2004; Van et al., 2004). 
CaVβs play a role as traffic regulators of the pore-forming α subunit to the plasma 
membrane and in modulation of biophysical properties of LTCC by associating with α1 
subunit (Dolphin, 2012).  
Characterization of the effects of β subunit interaction on the gating properties of 
LTCCs demonstrated a significant shift of the conductance-voltage (G-V) relationship 
toward more negative potentials in the presence of β2a in heterologously expressed 
channels, while the voltage dependence of the charge movements (gating currents) 
remained unchanged (Figure 8) (Neely et al., 1993). Furthermore, in addition to the 
steady-state voltage-dependence, it is well established that both the activation and 
inactivation kinetics are significantly altered in the presence of β subunits (Varadi et al., 
1991; Singer et al., 1991). CaVβ subunits increase the open probability (Po) in a single 
channel measurements causing a hyperpolarizing shift in the voltage-dependence of 
activation, and imparting unique profiles of voltage-dependent inactivation (Wakamori 
et al., 1999; Colecraft et al., 2002) , with β2a producing the most dramatic increase in 
channel open probability (Dzhura and Neely, 2003). Thus, CaVβs regulate biophysical 
properties of LTCC: increasing channel open probability (Po), causing a hyperpolarizing 
shift in the voltage-dependence of activation, and imparting unique profiles of voltage-
dependent inactivation. Furthermore, different β subunits confer a specific signature to 
LTCC voltage dependent properties. Different isoforms, when coexpressed with human 
α1E, have been shown to modulate inactivation of VGCCs expressed in Xenopus oocytes 
(Olcese et al., 1994). A study done in rat ventricular myocytes has demonstrated that 
four isoforms of Cavβ subunits, namely β1, β2, β3, and β4, contribute to an increase in the 
open probability of LTCC to different degrees (Colecraft et al., 2002). Among the 
different Cavβ subunits, Cavβ2a subunit seemed to produce the greatest enhancement in 
the current density compared to all other β isoforms (Alseikhan et al., 2002). The 
difference in the modulation confers by β subunit is present even between splice 
variance. In fact five different splice variants (β2a–β2e) that differ only in their N-termini 
where expressed in heterologous cells and each splice variance impart unique 
inactivation and single-channel-gating signatures (Takahashi et al., 2005).  
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In the heart β2 and β3 are the most abundant subunit expressed (β2 >β3), in particular it is 
reported that β2b is the most abundant transcript in ventricular myocytes compare to β2a 
and β3 (Hullin et al., 1992). The functional significance of having diverse CaVβ 
isoforms and splice variants in the heart is unknown. Knockout of β2 in mice is 
embryonic lethal due to impaired cardiac development that is secondary to a decreased 
L-type Ca2+ current (ICa,L) (Weissgerber et al., 2006). On the contrary, in a recent study 
it is reported that a cardiac-specific excision of β2 in adult mice substantially knocked-
down β2 protein (by 96%), but only moderately decreased ICa,L suggesting that CaVβ2 
may not be critical for α1C trafficking in adult ventricular myocytes (Meissner et al., 
2011). Additionally, increased expression of β2a has been seen in failing human hearts, 
which are prone to arrhythmias, and it has also been shown to play a role in pathological 
membrane excitability leading to cell death in adult cardiomyocytes (Hullin et al., 
2007). 
 
γ There are eight distinct γ isoforms (γ1–γ8). γ subunits are membrane proteins with a 
predicted four membrane-spanning segments and intracellular N- and C-termini. The 
cDNA of four γ subunit isoforms (γ4, γ6, γ7, and γ8) has been detected in human heart, 
although only γ6 expression has been confirmed at the protein level in rat heart (Shaw 
and Colecraft, 2013). 
 
2.1.7. Using Dynamic clamp to study the biophysical properties of 
LTCC 
The patch clamp technique was developed by Neher and Sakmann in the late ‘70s. This 
technique revolutionized the field of physiology and biophysics by allowing 
electrophysiologists to directly study the ion channel function. Therefore, the patch 
clamp technique can generate important information about the behavior of ion channels, 
transporters and pumps in various physiological setting allowing to understand the 
behavior of excitable cells in vitro and in vivo. Furthermore, it has facilitated the 
development of mathematical models of complex electrophysiological phenomena. 
 A powerful evolution of the patch clamp is the dynamic clamp technique that combines 
electrophysiological recordings and mathematical modeling in real-time. This allows for 
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the introduction of a virtual (computer-simulated) ionic current into a cell to test its 
impact on the cell electrical properties and excitability. The concept of dynamic clamp 
was first demonstrated in the ’90s by Tan and Joyner. They studied the artificial 
electrical coupling between isolated rabbit ventricular myocytes in a whole-cell clamp 
(Tan and Joyner, 1990). They did a simulation of two cells with a variable coupling 
resistance without physically coupling them to observe changes in the properties of each 
cell individually as a result of artificially providing electrical coupling between them 
(Tan and Joyner, 1990).  
Dynamic clamp has been used by several groups to studythe behavior of different 
excitable cells, mainly in the neuroscience field (Tan and Joyner, 1990; Sharp et al., 
1993; Wilders, 2006; Berecki et al., 2005; Berecki et al., 2007; Madhvani et al., 2011). 
We took advantage of this hybrid experimental-computation system to explore with 
great precision the different biophysical properties of ICa,L that could potentially serve as 
a therapeutic target for EADs suppression. 
 
In our experiments, we use the cardiac action potential model-UCLA model (Mahajan 
et al., 2008) containing five macroscopic conductances (ICa,L; the fast Na channel INa; 
the Na/K pump INaK; the Na/Ca exchanger INCX; and the Ca2+-dependent K rectifier IKs). 
Specifically, the formulation of ICa,L is an Hodgkin-Huxley-type formulation to allow us 
to modify specific parameters of ICa,L in a discrete manner, rather than changing the 
gating behavior of the channel, which can be more difficult to interpret. 
Figure 9. A diagram of our Dynamic Clamp set-up. The dynamic clamp is a 




A ventricular myocyte is whole-cell patch-clamped with an amplifier in current-clamp 
mode (Figure 9). The myocyte’s membrane potential (Vm) signal (red arrow) is 
digitized and input to a computer running the AP model. The computer calculates the 
ionic conductances that can be output in any combination to produce ICommand. In our 
case case, ICommand is ICa,L (blue arrow). ICommand is combined with a pacing AP stimulus 
and converted to analog before being input to the amplifier to be injected into the 
clamped myocyte. This alters the myocyte Vm, which is in turn sampled for the next 
computation. Thus, there is a dynamic, bidirectional relationship between Vm and 
model conductance output, at a sampling/computation frequency of 10 kHz. In our 
experiment a virtual ICa,L with programmable properties is injected into a cell in real 
time to study its effects on action potential characteristics without altering other existing 
ionic conductance in the cell. Using this technique, our laboratory was able to 
previously show that a ~5 mV leftward shift in half-inactivation potential and a ~5 mV 
rightward shift in half-activation potential, both of which lower the area encompassing 
the “window current” region, potently abolished EADs in rabbit ventricular myocytes 
(Madhvani et al., 2011). These studies strongly supported the relevance of ICa,L in EADs 
formation and showed that by manipulating only the ICa,L biophysical properties, EADs 
could be abolished, even though there may be many other ionic currents involved in the 
initial EADs genesis (Madhvani et al., 2011).  
 
 
This thesis investigated the relevance of the non-inactivating ICa,L (pedestal current) in 
the etiology of EADs using dynamic clamp technique. Furthermore, we tested the 
hypothesis that a decrease in the expression of Cavβ2 subunits in ventricular myocytes 




2.2.     Methods 
2.2.1. Ethical Approval 
All animal handling protocols were approved by the UCLA Institutional Animal Care 
and Use Committee and conformed to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health. 
 
2.2.2. Myocytes isolation 
Ventricular myocytes were isolated from three- or four-month-old male New Zealand 
white rabbits as previously described (Madhvani et al., 2011). The rabbits were first 
injected with heparin sulfate (1000 U) and sodium pentobarbital (100 mg/kg) 
intravenously. Adequacy of the anesthesia was confirmed by the lack of pedal 
withdrawal reflex, corneal reflex, and motor response to pain stimuli. Following 
excision, the heart was submerged in Tyrode's buffer solution containing (in mmol/L): 
136 NaCl, 5.4 KCl, 1 MgCl2, 0.33 NaH2PO4, 0.2 CaCl2, 10 Glucose, and 10 HEPES 
adjusted to pH 7.4. Using a retrograde Langendorff perfusion system, the rabbit’s 
excised heart was first perfused with Tyrode’s solution until all blood was washed out 
thoroughly; then, Tyrode’s solution containing 0.8mg/mL bovine serum albumin and 
1.65mg/mL collagenase was constantly perfused for about 30 to 40 minutes to ensure 
sufficient digestion time. The enzyme-containing solution was washed out after the 
digestion time and the heart was submerged and mechanically torn apart with forceps in 
Tyrode’s solution containing 0.2 mmol/L Ca2+. The pieces of the tissue were swirled in 
the solution to aid cell dissociation. The dissociated myocytes were then washed several 
times in 1.8 mM Ca2+-containing Tyrode's buffer solution using centrifugation to 
remove as much dead cells as possible following the isolation. The myocytes were 




2.2.3. Adenoviral construct 
RNA interference (RNAi) is mechanism of specific gene-silencing at the post-
transcriptional level in which small RNAs molecules, called siRNAs, inhibit the 
expression of a gene of interest, by causing the destruction of the specific mRNA. 
Esperimentally, this process can be induced by introduction of synthetic small interfece 
(siRNAs) into the cells or by intracellular generation of siRNA from vector driven 
expression of the precursor small hairpin (sh) RNAs. shRNA has been shown to be 
more effective and potent in silencing genes. In these “method”, a double-stranded 
oligonucleotide containing the siRNA sequence linked by a ~9 nucleotide loop is cloned 
in plasmid or viral vectors to endogenously express shRNA which is subsequently 
processed in the cytoplasm to siRNA. To delivery the plasmid into the cell we use 
adenoviruses. This type of virus is suited for short-term shRNA expression and gene 
silencing since the viral DNA is not incorporated in the host genome. To delivery the 
plasmid into the cell we use adenovirus. This type of virus is suited for short-term 
shRNA expression and gene silencing since the viral DNA is not incorporated in the 
host genome.  
We design a short hairpins specific for Cavβ2 mRNA transcripts. The shRNA sequence 
is: 5’-AAAAAAACATGAGGCTACAGCATGAATTGGATCCAATTCAGCTGTAG 
CCTCATGTTTTTTT- 3’. This shRNA was subcloned into adenovirus plasmids under 
the human U6 promoter, which have been widely used to induce RNAi in mammalian 
cells. Within the same plasmid is a CMV promoter driving the expression of GFP. The 
adenovirus production was done following a protocol previously designed (Luo et al., 
2007). The control virus is an another adenovirus which containing just GFP (without 
the shRNA). The viruses were first propagated in transfected HEK 293 cells and 
maintained at 5% CO2, 37 °C in Minimum Essential Media (MEM) (Life Technologies) 
with Earle’s salts and L-glutamine, supplemented with 5% fetal bovine serum (FBS), 
and 1% Penicillin-Streptomycin (pen/strep) antibiotic solution. The viruses were then 
purified from the HEK 293 cells once enough fluorescence of GFP was observed under 
fluorescence microscopy.  
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2.2.4. Myocytes culture and infection 
Ventricular myocytes dissociated in 1.8 mM Ca2+-containing Tyrode's buffer solution 
were subsequently washed in sodium bicarbonate buffered Medium 199 with Earl's 
salts, L-glutamine, 1% penicillin/streptomycin and 5% bovine serum (Cellgro) at pH of 
7.3 to 7.4 that has been incubated at atmosphere of 5% CO2 for at least an hour. The 
myocytes were then plated on Geltrex coated glass coverslip at densities of about 104 
cells/cm2 for 3 to 4 hours to allow them to attach to coverslips prior to adenovirus 
infection. Before the infection, the media in the dish containing attached myocytes was 
replaced with Medium 199 supplemented with 1X insulin-transferrin-selenium (ITS) 
and 15 µM Blebbistatin, for nutrients and reduced contraction. One dish that served as a 
control was prepared for GFP-only virus infection, while another dish was prepared for 
β2 shRNA-GFP virus infection. 
2.2.5. Electrophysiology 
For dynamic clamp experiments, freshly dissociated ventricular myocytes bathed in 
Tyrode’s buffer solution were then patched under whole-cell current clamp. The 
myocytes were first patched in Tyrode’s solution before 600 µM H2O2 was perfused to 
induce EADs. Once EADs were seen in consecutive APs, Tyrode’s solution containing 
a specific L-type calcium channel blocker, nifedipine (20 µM) and 0.6 mM H2O2 was 
perfused. Once the nifedipine effect showed, the dynamic clamp was turned ON. The 
charges (q) on the membrane was measured by taking the integral of the capacitative 
current with a 5 mV pulse. The membrane capacitance was calculated using the 
equation C = q/V. The capacitance value is then inputted into the parameters shaping 
the virtual ICa,L on real time experimental interface (RTXI) for each cell. Cells were 
paced at 6 s pacing cycle length. 
Cultured myocytes: Whole-cell current clamp was conducted between 36-48 hr after the 
myocytes were infected with the viruses. All recordings were measured using AxoPatch 
200B (Axon Instruments). Whole-cell patch-clamp recordings were performed using 
electrodes with tip resistance of 1-3 MΩ borosilicate pipettes. The pipette solution 
contained (in mmol/L): 110 K-Aspartate, 30 KCl, 5 NaCl, 10 Hepes, 0.1 EGTA, 5 
MgATP, 5 creatine phosphate, 0.5 cAMP, adjusted to pH 7.2. All electrophysiological 
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experiments were performed at 34-36°C. 600 µM H2O2 was used as an oxidative stress 
to induce EAD in the myocytes. ICa,L recordings were done using the Tyrode’s buffer 
and pipette solutions described above, with the following changes: 10 μM Tetradotoxin 
(TTX) was added to the extracellular solution to eliminate Na+ conductance, and K+ was 
replaced with Cs+ to block K+ conductance. ICa,L was calculated by subtracting the 
current recorded after addition of 20 μM Nifedipine from the total current. The steady 
state activation and inactivation curves were constructed as previously described 
(Madhvani et al., 2011). The steady state activation curves: divide the peak I–V curve 
by the driving force to calculate conductance (G) and divide G by Gmax. The steady 
state inactivation curves were constructed by graphing the normalized peak current 
during a test pulse at +10 mV after a 300 ms inactivating pulse at different voltages. 
Boltzmann distribution fitting was used to estimate the half-activation/inactivation 
potential of the steady state activation/inactivation curves. The Boltzmann distribution 
fitting for steady state activation is given by the following equation: 
(Imax)/(1+EXP((Vhalf-Vm)/slope)); while the steady state inactivation is given by the 
following equation: (Imax-Imin)/(1+EXP((Vm-Vhalf)/slope))+Imin. 
Oocytes: Xenopus oocytes of stages V-VI were prepared and injected with 0.05 μl of 
cRNA containing 0.1 to 1 mg/mL of α1c/α2δ, α1c/α2δ/β3, and α1c/α2δ/β2a in equal 
molarity. The oocytes were then incubated for 4-7 days prior to electrophysiological 
experiments at 18°C in an amphibian saline solution containing 50 μg/mL gentamycin 
(Invitrogen). Immediately preceding each experiment, each oocyte was injected with 0.1 
μl of 50 mmol/L BAPTA, which is 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-
tetraacetic acid tetrakis (acetoxymethyl ester) (Sigma). Cut-open oocyte voltage clamp 
technique was used to obtain electrophysiological recording of the injected oocytes. The 
oocytes were bathed in a solution containing (in mmol/L): 105 NaMES, 10 HEPES, 10 
CaMES, and 0.1 Ouabain, adjusted to pH 7.0. The internal solution contained 110 
mmol/L K-Glutamate and 10 mmol/L HEPES, also adjusted to pH 7.0. Steady state 
activation curves were fit to a Boltzmann given by the following: (Imax) / 
(1+EXP(z(Vm-Vhalf)/(RT/F))). Steady-state inactivation curves were fit with a 
Bolztmann distribution given by the following equation: (Imax-Imin)/(1+EXP(z(Vm-




2.2.6. Quantitative Real Time Polymerase Chain Reaction (qRT-
PCR) 
RNA was isolated from myocytes infected with GFP only and myocytes infected with 
β2 shRNA-GFP following 24-48 hr of culturing. The isolation was done using Trizol 
(Invitrogen) and the RNAs were subsequently reverse-transcribed with gene specific 
primers using the Omniscript RT kit (Qiagen). The primer sequences used were as 
follows: β2a forward primer (5’-GTA CGC GCG AGT CCT GGG C-3’), reverse primer 
(5’-GTC GCT CAG CTT CTC TGC GC-3’); β2b forward primer (5’-GCA GCT CGC 
TCG TGC CTG C-3’), reverse primer (5’-CAG GAG CGA CGA GAG CTG AG-3’); 
β3 forward primer (5’-AGA CTA TGC GGA CGC CTA CCA-3’), reverse primer (5’-
GCT AGG GTG GGA ACA TCA GGA-3’); GADPH forward primer (5’-CCT GCA 
CCA CCA ACT GCT TAG-3’), reverse primer (5’-ATG ACC TTG CCC ACG GCC 
TT-3’). GAPDH transcript levels were used as a baseline for normalization of the 
relative fluorescence obtained from RT-PCR. 
 
2.2.7. Dynamic Clamp 
This technique combines mathematical model and biological systems for 
electrophysiological allows for a computer-simulated ionic conductance to be injected 
into a live cell in real-time using a real-time experimental interface (RTXI). We use a 
UCLA ventricular myocytes model. The virtual ICa,L, with the properties of the native 
ICa,L is injected into the myocytes. To predict ICa,L and its Ca2+-dependent inactivation, 
our ventricular myocyte model also computes intracellular Ca2+ cycling. To predict the 
spatiotemporal distribution of intracellular calcium, average [Ca2+] was computed in 
four different cellular compartments, namely the "submembrane space" in proximity of 
the sarcolemma (Cs) and the "bulk myoplasm", the "junctional SR" (JSR) and "network 
SR" (NSR) (as previously, (Shiferaw et al., 2003); (Mahajan et al., 2008); (Madhvani et 
al., 2011). The main Ca2+-regulated ionic conductance were also included in the model 
(i.e. the fast sodium current (INa), the Na+/K+ pump current (INaK) the Na+/Ca2+ exchange 
current (INCX) and the Ca2+-dependent slow component of the delayed rectifier 
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potassium channel (IKs). Calcium modulated currents sense the [Ca2+] at submembrane 
space (Cs) which is higher than the global [Ca2+] (Ci) (Weber et al., 2002). The average 
Cs is used to calculate Ca2+-dependent inactivation (CDI) in the ICa,L formulation, while 
Ci was acquired during the course of the experiments to predict the amplitude and shape 
of the Cai transient.(Mahajan et al., 2008) (Madhvani et al., 2011). Briefly, the Ca2+ flux 
into the cell due to ICa,L is given by:  
     ; 
where Cs is the submembrane concentration in units of mmol/L. PCa is the permeability 
of Ca (0.0054 m/s), V is the voltage, F is the Faraday’s constant, T is temperature. Po 
was formulated as:  
 
where d is the voltage-dependent activation gate, f is the voltage-dependent inactivation 
gate and q is the Ca2+-dependent inactivation gate. 
Data Analysis. All data acquired on G-Patch were analyzed on Analysis, both of which 
are custom-made. APD at 90% repolarization (APD90) was measured by using a 
custom-made software, AP analyzer. EAD amplitude was calculated by taking the 
difference in Vm from the inflection point where dV/dt is 0 to the peak of the EAD 
where dV/dt is also 0. Only the EAD having the largest voltage excursion was included 
in the analysis for cells displaying APs with multiple EADs. % EAD is reported as the 
percentage of APs that displayed at least one EAD. Error bars show the standard error 
of the mean (SEM). The control parameters in the ICa,L formulation were determined by 
fitting formulated current to experimental nifedipine-sensitive ICa,L records (Madhvani et 
al., 2011) using Berkeley Madonna and then implemented for dynamic clamp in Real-
Time eXperiment Interface RTXI (www.rtxi.org) (Lin et al., 2010). The 






















2.3.     Results 
This project has been developed in collaboration with Dr. Weiss, Dr. Qu, Dr. Garfinkel 
and Dr. Karaguezian at University of California-Los Angeles (USA). 
2.3.1. Reducing the non-inactivating component of ICa,L potently 
abolished EADs 
Using dynamic clamp technique (Dorval et al., 2001) in isolated rabbit ventricular 
myocytes under hypokalemia or oxidative stress conditions, our laboratory previously 
identified two interventions of the L-type Ca2+ channel (LTCC) biophysical properties 
that could potently suppress EADs occurrence: i) a ~5mV depolarizing shift of the 
steady-state activation curve and ii) a ~5mV hyperpolarizing shift of the steady-state 
inactivation curve. These results point out that a reduction of the ICa,L “window current” 
may represent an effective maneuver to suppress EADs without blocking the early peak 
ICa,L required to maintain normal excitation-contraction coupling (Madhvani et al., 
2011). Furthermore other parameters can also affect the ICa,L “window current” and in 
this study, taking advantage of the dynamic clamp technique we systematically 
evaluated the sensitivity of EADs to the non-inactivating (late component) of ICa,L,. 
Thus, we tested the hypothesis that EADs can be suppressed by selectively targeting the 
ICa,L non-inactivating component. 
The inactivation of L-type Ca2+ channels (LTCC), due to Voltage-dependent 
inactivation (VDI) and Ca2+-dependent inactivation (CDI) mechanisms (Catterall, 2011) 
is incomplete during the time course of an action potential (AP). The residual, non-
inactivating component known as ICa,L pedestal (Rose et al., 1992);(Qu and Chung, 
2012) has a large impact on the voltage level and duration of the AP plateau. The early 
afterdepolarizations (EADs) are largely induced by the reactivation of L-type Ca2+ 
currents (ICa,L) that occurs at the range of membrane potential from 40 to 0 mV, called 
“window current” region (January and Riddle, 1989; Antoons et al., 2007). Therefore 
the generation of EADs is related on the fraction of LTCC that may be available when 
the AP repolarizes into this voltage “window” range. In our laboratory we have 
previously reported that one of the effects of H2O2 in producing EADs is to enhance the 
non-inactivating component of ICa,L pedestal from ~3% to ~10% of the peak current 
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(Madhvani et al., 2011). To determine the relevance of the non-inactivating pedestal 
ICa,L on EAD genesis, we used dynamic clamp to alter the pedestal current parameter 
while keeping all other biophysical parameter of ICa,L unchanged. In our experimental 
protocol utilizing the dynamic clamp technique, we first paced every 6s a rabbit 
ventricular myocyte to record the AP in the current clamp mode in control condition. 
The myocyte was then exposed to 600 μmol/L H2O2 until EAD regime appeared 
consistently. After the induction of EADs, the endogenous ICa,L was blocked with 20 
μmol/L Nifedipine (with H2O2 still present) which markedly shortened APD and 
abolished EADs. The dynamic clamp was then turned on, adding the virtual ICa,L 
computed from the UCLA rabbit ventricular AP cell model (Mahajan et al., 2008), 
whose properties which had been adjusted to simulate the previously analyzed effects of 
H2O2 on ICa,L gating properties. Injection of this “H2O2-modified” virtual ICa,L 
effectively restored the electrical properties of the myocyte membrane, resulting in AP 
prolongation and the reappearance of EADs. At the beginning of the experiment we 
measured cell capacitance for each cell and this parameter is imputed in the model to 
correctly scale the virtual ICa,L to the size of the cell.  
Reducing the pedestal current from 10% to 4% completely suppressed EADs 
occurrence (Figure 10) and also restored normal AP morphology shortening APD to 
186 ± 2 ms (Figure 10). To notice is that this change in the parameter was done in the 
continuous presence of 0.6 mM H2O2. 
The results from dynamic clamp experiments show that reducing the ICa,L “window 
current” region by lowering the non-inactivating pedestal component of ICa,L from 10% 
(the baseline pedestal in the presence of H2O2, Madhvani et al., 2011) to 4% (Figure 




This result strongly suggests that the ICa,L pedestal current has an equivalent promise to 
the half-activation and half-inactivation potentials, previously identified by Madhavani 
and colleagues, as a novel anti-arrhythmic target to suppress EADs formation 
(Madhavani et al 2011). Note that all these promising therapeutic intervention, that 
potent suppress cardiac arrhythmias, are modifications of ICa,L steady-state properties 




Figure 10. A reduction in the non-inactivating (pedestal) ICa,L potently 
suppresses EADs and restores APD. A, B) Enlarged view of the steady-state 
activation and inactivation curves of ICa,L shows changes made to the non-
inactivating component (pedestal). Under dynamic clamp and in the presence of 
H2O2, we evaluated the effect of lowering the non-inactivating pedestal from 10% 
(A) to 4% of the peak current (B). C) Representative AP recorded in dynamic clamp 
under the conditions shown in (A). Note that lowering the pedestal current to 4% (B) 
eliminated EADs and restored a normal APD (E-F). E-F) The proportion of APs 
displaying EADs and APD90 under two different pedestal amplitudes respectively. 
Individual experiments are shown as solid circle, the means for all experiments are 
plotted as open rectangles (n = 4, from 4 rabbits). Error bars indicate SEM. 
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2.3.2. Different CaVβ subunit isoforms confer characteristic ICa,L 
biophysical properties 
Using the dynamic clamp we point out three highly effective targets to suppress EADs 
formation: the half-activation and half-inactivation potentials and the non-inactivating 
pedestal current. LTCCs are multiprotein complexes in which CaVβ subunits modulate 
the voltage dependence properties of the channel (Figure 8), therefore changing the 
height of the “window current” (Olcese et al., 1994; Neely et al., 1993). Thus, sice 
EADs are sensitive ont he biophysical properties of ICa,L, we explored whether 
modifying LTCC β subunit composition is a suitable therapeutic strategy to prevent 
EADs. 
 
Olcese and colleagues have previously demonstrated that different Cavβ modulatory 
subunits, when expressed with LTCC pore-forming subunit α1E or α1C the Ca2+ channel 
profoundly modulate activation and inactivation properties of the channel (Neely et al., 
1993; Olcese et al., 1994). Similar results were obtained in voltage clamp experiments 
 
Figure 11. Influence of Subunit Composition on the Biophysical Properties of 
LTCCs. The experimental steady-state activation and quasi-steady-state inactivation 
curves from various L-type Ca2+ channels compositions. The pore forming α1C 
subunit was expressed with the modulatory subunit α2δ (green circle) only or with 
β2a subunit (blue diamond) and β3 (violet triangle). Different β subunit conferred 
specific activation and inactivation properties to the channel, resulting in a 
significant variation in the window current region. The coexpression of β2a subunit 
produces a left shift in the activation curve and a larger non-inactivating pedestal (as 
compare to α1C/α2δ-1 channels). Thus β2a favors a larger window current region 







































where we coexpressed the human pore forming subunit α1c and the auxiliary α2δ 
subunits of LTCC with either Cavβ2a or Cavβ3 subunit or without any Cavβ subunit in 
Xenopus oocyte system. Tail currents from 20 ms pulses were used to construct steady-
state activation curves. Furthermore, considering that the average duration of a human 
cardiac AP is approximately 300 ms, we assessed the availability of channels (steady 
state inactivation curves) at this time point using a two-pulse protocol. Measuring the 
steady state activation and quasi steady state inactivation properties of each combination 
we demonstrated that α1c/α2δ/β2a subunits exhibit higher non-inactivating pedestal 
current than α1c/α2δ/β3 and α1c/α2δ. Furthermore, both β2a and β3 subunits modulated 
steady state activation curve of LTCC shifting the curve to a more hyperpolarized 
potential (β2a V1\2 act = 22.51 and β3 V1\2 act = 24.71) facilitating the opening of the 
channel at more negative potentials compared to LTCC without any β subunits (V1\2 act 
= 34.64) as shown in Figure 11. Thus, the presence of β subunits increases the “window 
current” region by shifting the half-activation potential toward hyperpolarized 
potentials. Furthermore, β2a subunit subunit, which are abundantly expressed in 
ventricular myocytes (Hullin et al., 2003), give rise to LTCCs with voltage-dependent 
properties favoring EADs formation because it enhances the activation of ICa,L , as well 
as increases the probability of ICa,L reactivation. 
 
2.3.3. Silencing of CaVβ2 in rabbit ventricular myocytes using 
shRNA 
β2 subunit displays properties that appears to favor ICa,L reactivation that leads to EADs 
genesis. Considering this assumptions, we hypothesized that a reduction in β2 subunit 
content in rabbit ventricular myocytes should generate ICa,L with an overall voltage 




In order to reduce β2 subunit expression in adult myocytes, we designed a short hairpin 
RNA (shRNA) against Cavβ2 that targets both the endogenous Cavβ2a and Cavβ2b 
subunits. An adenoviral vector that bicistronically encodes for the shRNA (short hairpin 
RNA) against β2 and gene reporter, Green Fluorescent Protein (GFP) were engineered 
and transduced into myocytes (siβ2 cells). Our control vector consisted in an adenoviral 
construct that encoded only for the gene reporter GFP (control virus). We used 
adenoviruses, both siβ2 (silencing of β2) and control virus to infect freshly dissociated 
rabbit ventricular myocytes. After 24-48 hours of incubation, the myocytes were 
examined under a fluorescence microscope verifying the virus tranduction using GFP 
reporter gene (Figure 12). To verify the extent of β2silencing in myocytes infected with 
adenovirus, a quantification of the mRNA levels of subunits in rabbit ventricular 
myocytes were done using RT-PCR. 
 
Figure 12. Efficiently transduction of adenoviral construct. Adult rabbit 
ventricular myocytes infected with adenoviral constructs (top, middle) or not infected 
(bottom) cultured for ~36 hours. The trasduction of the virus into target cells can be 




The levels of β2a and β2b subunit mRNA transcripts in myocytes infected with shRNA 
against β2 (siβ2 myocytes) were both lower compared to those infected with control 
virus (Figure 13). Furthermore, we observed an increase in the expression of β3 mRNA 
transcript in siβ2 myocytes compared to control myocytes (GFP only) that could be a 
compensatory mechanism that the myocytes expressed to allow for LTCCs to be 
expressed and trafficked to the cell membrane despite the silenced β2a and β2b subunits. 
 
2.3.4. CaVβ2 silencing prevents EADs formation in rabbit ventricular 
myocytes 
Since β2 showed proarrhythmogenic properties, we asked whether the reduction in β2 
protein level obtained with shRNA, was associated with a reduction in the overall ICa,L 
“window current” region that has been implicated in EADs genesis. We recorded 
cardiac APs in current clamp mode in ventricular myocytes cultured for 36-48 hours, in 
regular Tyrode’s buffer solution with a pacing cycle length (PCL) of 6s. After 2 minutes 
we perfused Tyrode’s solution containing 600 μM H2O2. APs recorded from control 
myocytes (GFP only) exhibited EADs (Figure 14, top panel), instead of siβ2 myocytes 
that did not show EADs in oxidative stress condition as shown in Figure 14, bottom 
panel. We plotted the percentage of APs showing EADs (% AP with EAD) in the two 
groups of cells. The % was 32.6 ± 6.1% in control and 0% in siβ2 myocytes infected. 
 
Figure 13. β2 silencing decreases the expression of β2a and β2b in rabbit 
ventricular myocytes. Relative expression of β2a, β2b and β3 transcripts by RT-PCR 
in myocytes infected with control adenovirus (blue) or siβ2 (red). The relative 






















Note that all siβ2 myocytes that we have tested so far (n=8) did not display EADs 
(Figure 15 B). 
Furthermore, the two groups of cells showed similar AP durations measured at 90% 
repolarization (APD90) in Tyrode’s solution: control 0.157 ± 0.02 s and in siβ2 0.151 ± 
0.027s (Figure 15 A). On the contrary, the control myocytes exhibited longer APD90 
during exposure to 0.6 mM H2O2 with an average of 0.940 ± 0.5 s, while siβ2 did not 
show a significant increase in the action potential duration (APD90 0.144 ± 0.024) 
compared to the AP recorded in regular Tyrode’s (Figure 15 A). These results suggest 
that ventricular myocytes with lower expression of Cavβ2 subunits are more resistant to 
EADs formation and APD as well. We next asked whether this absence of EADs in siβ2 
ventricular myocytes was related to a change in the ICa,L “window current”. We then 
characterized ICa,L properties performing electrophysiological experiments in voltage-
clamp configuration.  
 
 
Figure 14. CaVβ2 silencing prevents EADs formation in ventricular myocytes. 
Top) Train of APs recorded from control rabbit ventricular myocytes (infected with 
GFP only) stimulated with pacing cycle length of 5 s at 35–37C in Tyrode’s 
solution or in the presence of 600 μM H2O2. Bottom) As in Top, but recording from 
a myocyte infected with shRNA against β2. Note that H2O2 did not induce EADs in 
β2-suppressed myocytes.  
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During the experiments we perfused bath solution and 20 μM Nifedipine (ICa,L 
inhibitor). By analytical subtraction, Nifedipine-sensitive currents were isolated from 
the total current of the cell (Figure 16). 
 
The ICa,L amplitudes were then normalized by membrane capacitance of the cell 
measured before starting the experiment. (Figure 17 A). Averaging all the experiments 
performed at each membrane potential, we found that, for example +10 mV the current 
density was 6.61 ± 0.81 pA/pF for siβ2 and 6.67 ± 0.51 pA/pF for control indicating that 
reduction in β2 subunits (siβ2) did not significantly alter ICa,L density compared to 
control myocytes (Figure 17 A). By constructing steady-state activation and inactivation 
curves averaging all the experiments, we found that the silencing of β2 (less β2 content) 
produced a ~+4 mV shift of the steady-state half-activation potential (V1/2 act) and ~-1 
mV left shift in the steady-state inactivation curve (V1/2 inact) (Figure 17 B). The 
reduction in β2 content (β2a and β2b) decreased the height of the ICa,L “window current” 
Figure 15. CaVβ2 knock down protects cardiac myocytes from AP prolongation 
and oxidative-stress-induced EADs A) The plot shows the distribution of action 
potential duration measured at 90% repolarization (APD90) measurements for control 
(blue) and β2 knock down myocytes (red) exposed to Tyrode’s solution and after the 
exposure to 600 μM H2O2 . All values are mean ± SEM. B) Box plot showing the 
percentage of APs with EADs in control myocytes (blue) and β2 knock down 
myocytes (red). Center line, median; box limits, 25th and 75th percentiles; n, number 





































region by shifting ICa,L steady-state activation curve to more depolarized potentials 
without significantly affect ICa,L peak. 
 
 
To conclude, our results show that down-regulation of β2 causes an overall reduction of 
the “window current” region shifting the steady state activation curve toward more 
 
Figure 17. Reduction in Cavβ2 subunits did not alter the peak current density of 
ICa,L but modified the size of the ICa,L window current region. A) Current–
voltage (I–V) relationship for ICa,L (normalized to the capacitance of the cells) in 
control (blue circles) and siβ2 (red circles) myocytes (n = 3). B) Mean of steady-state 
activation and inactivation curves for ICa,L in control (blue circles) and β2 knock down 
(red circles) myocytes (n = 3 each). Note in β2 knock down myocytes the shift of 
steady-state curves to the right results in a decrease in ICa,L “window current” region. 
All values are mean ± SEM. 
 
Figure 16. Representative ICa,L recording from infected myocytes. A-B) Voltage 
clamp recording of nifedipine-sensitive ICa,L current at -40 and 0 mV, in response to 
the protocol reported above. Representative current traces from myocytes infected 




















































depolarized potential. This change in the ICa,L voltage dependence properties 
successfully prevents oxidative stress-mediated EADs in ventricular myocytes. Our 
results are a first proof of concept of the finding that a tiny shift in the steady state 




2.4.     Discussion 
My PhD training at University of California-Los Angeles, focused on the mechanisms 
of cardiac arrhythmias. Specifically, I have investigated the role of voltage gated L-type 
calcium channel (LTCC) in the etiology of early afterdepolarizations (EADs).  
EADs are membrane potential oscillations during the repolarizing phase of the 
ventricular action potential (AP) (phase 2 or 3) (Figure 6). These events are highly 
arrhytmogenic because they can generate a new AP that propagates to the surrounding 
tissue disrupting the normal sinus rhythm. It is widely accepted that EADs are important 
as cellular triggers to ventricular tachycardia (VT) and ventricular fibrillation (VF) 
(Figure 5). EADs are mainly due to either abnormally decreased outward currents, 
increased inward currents, or both, classically defined as reduced repolarization reserve. 
Even though different ionic currents are involved in the AP and can contribute to EAD 
formation, reactivation of ICa,L plays a central role in providing a regenerative inward 
current required for EADs to propagate, thus causing triggered activity at the tissue 
level (January and Riddle, 1989; January et al., 1988). Understanding the mechanisms 
of EADs formation is critical to identify appropriate strategies to prevent EADs-related 
cardiac arrhythmias. Most EADs are initiated between -40 and 0 mV, corresponding to 
the range of membrane potentials where the steady-state activation and inactivation 
curves of ICa,L overlap, often referred to as the “window current” region (Figure 6) 
(January and Riddle, 1989; Antoons et al., 2007;January & Riddle, 1989). In a previous 
study from our laboratory we used the dynamic clamp technique to explore 
systematically how biophysical properties of ICa,L could be modified to suppress EADs 
without impairing excitation-contraction coupling (Madhvani et al., 2011). Isolated 
rabbit ventricular myocytes were first exposed to oxidative stress (H2O2) in order to 
generate a EADs regime, after which their endogenous ICa,L (blocked with Nifedipine) 
was replaced by a virtual ICa,L with tunable parameters, in dynamic clamp mode. This 
previous work demonstrated that EADs are highly sensitive to subtle changes in the 
half-activation or half-inactivation potentials of ICa,L, suggesting that a reduction of the 
ICa,L “window current” may represent an effective maneuver to suppress EADs without 
blocking the early peak ICa,L required to maintain normal excitation-contraction 
coupling. However other parameters also affect the ICa,L “window current”; in this 
study, we took advantage of the dynamic clamp technique to systematically evaluate the 
90 
 
sensitivity of EAD to the non-inactivating (late component) of ICa,L, testing the 
hypothesis that EADs can be suppressed by selectively targeting this ICa,L parameter. 
 
What is the role of the late component of L-type calcium current in EADs genesis? 
To test the susceptibility of EADs to the non-inactivating component of ICa,L, we 
selectively modified its amplitude in ventricular myocytes exhibiting H2O2-induced 
EADs using dynamic clamp approach. The reduction of non-inactivating component of 
ICa,L pedestal current effectively suppresses EADs and restores APD to a normal value 
(Figure 10). An important novel contribution of the present study is the finding that the 
ICa,L pedestal current has an equivalent promise to the half-activation and half-
inactivation potentials, previously identified by Madhavani and colleagues as a novel 
anti-arrhythmic target to suppress EADs formation (Madhvani et al., 2011).  
Thus, from our dynamic clamp studies, we predict that drugs or genetic interventions 
that leave peak ICa,L and hence excitation-contraction coupling intact but selectively 
suppress one of these valuable targets (steady state activation, inactivation or pedestal 
current) will be effective at eliminate EADs.  
We are currently directing our investigations on the voltage dependence properties of 
the channel LTCC in order to develop a genetic approach to prevent EADs-mediated 
arrhythmias. L-type calcium channel are multimeric complexes they are made up of a 
pore-forming α1C subunit that co-assembles with modulatory subunits such as β and α2δ1 
(Figure 7). 
Since the early 90’s, It is known that different β subunits modulate the biophysical 
properties of LTCC (Figure 8) (Perez-Reyes et al., 1992; Neely et al., 1993; Olcese et 
al., 1994). 
In voltage clamp experiments we measured the steady state properties of ICa,L in the 
presence of β2a and β3 (Figure 11). We confirmed that CaVβ modified the steady state 
properties of LTCC. As shown in Figure 11, β2a subunit, which are abundantly 
expressed in ventricular myocytes (Hullin et al., 1992), give rise to LTCCs with 
voltage-dependent properties favoring EAD formation. In fact, β2a enhances the 
activation of ICa,L and increases the probability of ICa,L reactivation, in which both cases 
would lead to EAD formation following previous dynamic clamp results. Our findings 
are consistent with prior reports demonstrating the pro-EAD effects of the β2a subunits, 
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particularly due to phosphorylation by CaMKII (Koval et al., 2010). Interestingly, 
several groups have demonstrated that the β2 subunits are the most abundant in the heart 
(Hullin et al., 2003; Hullin et al., 2007; Colecraft et al., 2002). Furthermore it has been 
shown a significant increase of β2a subunit expression in cardiomyocytes in mice model 
of heart failure (Hullin et al., 2007), a condition known to favor EADs. Other 
quantitative studies have suggested that in heart β2b expression is higher than β3 and β2a 
(Hullin et al., 2003).  
According to these findings and dynamic clamp data, we hypothesized that genetic 
interventions to tune the biophysical properties of ICa,L by altering its subunit 
composition could be an effective non pharmacological strategy to suppress EADs in a 
highly specific manner.  
Since there is a consensus that β2 is highly expressed in the myocytes (Hullin et al., 
2003; Colecraft et al., 2002) and because β2a shows pro arrhythmogenic characteristics, 
we delivered a shRNA into adult ventricular myocytes using an adenoviral construct 
(Figures 12 and 13). By silencing β2 in cultured myocytes, we established that a 
reduction in the expression of β2 affects the steady state activation properties of LTCC 
in a favorable way, shifting the activation curve to the right. This small change in the 
steady-state activation (~+4mV) potently prevents EADs formation in ventricular 
myocytes (Figures 15 and 17). This small change in the steady-state activation 
recapitulates the previous finding of Madhavani et al, in which they demonstrate that 
EADs are sensitive to small change in the LTCC in steady-state activation curve (~+4-5 
mV). Interestingly, the effect on the steady-state activation property is without causing 
any changes in the current density of ICa,L (Figure 17). This aspect is relevant from a 
therapeutic stand point because functional LTCCs are necessary for providing the major 
passageway for Ca2+ entry and Ca2+ signaling into the cell very critical for muscle 
contraction. Most importantly, our results show that lowering the levels of β2 subunits 
completely abolish the EAD occurrence demonstrating that decreasing β2 protects the 
cell from oxidative stress insult. Conversely, control myocytes from the same batches 
exhibit significant action potential prolongation and all cells develop EADs after H2O2 
exposure. 
These findings demonstrate that manipulation of the subunit composition can be an 
effective strategy for altering the steady-state properties of ICa,L. A major potential 
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advantage of using β subunits is their high selectivity for the LTCC pore-forming α1 
subunit, minimizing side effects that common pharmacological therapy normally has. 
Thus, our results offer a proof of concept for a gene-therapy-based antiarrhythmic 
strategy that could effectively suppress EAD-and their arrhythmogenic concequences  
We recognized that before considering the clinical utility of these findings, the results 
from this preliminary study need to be tested in perfused hearts and and animal models, 
possibly using a new generation of cardiac specific adeno-associated viral vectors 
(AAV 9) (Bish et al., 2008) in order to validate the efficacy of this interventions. 
 
On a parallel path, using a more conventional pharmacological approach, we are 
screening compounds that can potentially affect one of the newly identified ICa,L 
biophysical parameters to which EADs are particularly sensitive, in order to identify 
new antiarrhythmic agents. We know that conventional Ca2+ channel blockers such as 
nifedipine, are highly effective at suppressing EADs mainly because they 
indiscriminately block ICa,L. However, by blocking peak ICa,L, these drugs also potently 
suppress excitation-contraction coupling, precluding clinical usefulness for EADs 
suppression. In this context an ideal Ca2+ channel drug for suppressing EAD-mediated 
arrhythmias would leave peak ICa,L intact to preserve normal excitation-contraction 
coupling, and for example, selectively blocks the late ICa,L reactivated during 
repolarization when AP plateau enters the “window” voltage range. This is something 
possible if we consider that recently Ranolazine, a selective blocker of the late Na+ 
current (INa) which leaves the peak INa intact, has been approved and it is already in 
clinical for treatment in chronic angina patients (Belardinelli et al., 2006; Zerumsky and 
McBride, 2006). 
 
While this study has greatly contributed to our understanding of EADs genesis and 
identified new strategies for their suppression, there are certain experimental limitations 
that deserve to be discussed. One important consideration is that this study was 
performed in rabbit ventricular myocytes, which differ in some respects from human 
ventricular myocytes. However, their L-type Ca2+ current properties are generally 
similar (Grandi et al., 2010; Verkerk et al., 2011). To efficiently delivery adenoviral 
constructs in isolated adult myocytes, we have to maintain cells in culture for 24-48 hr. 
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We are aware to the fact that cultured myocytes are subject to changes in morphology 
and conductances compared to fresh dissociated myocytes (i.e. rounding of the edges of 
the ventricular myocytes and reduction in AP duration due to a decrease in the overall 
channel expressions). In fact, it will be important validate the results in an intact heart or 
in the animal model. Another limitation of this study is that in our dynamic clamp 
experiments the virtual programmable ICa,L do not carry Ca2+ ions. Therefore, the 
injected virtual ICa,L do not trigger SR Ca2+ release. Nevertheless, the depolarizing 
current has the shape and duration dictated by the ICa,L model parameters and the 
membrane voltage. While this can be viewed as a limitation, it can also be considered 
an experimental advantage suggesting that EADs formation can have a purely electrical 
etiology that does not involve the biochemical consequences of Ca2+ influx. Despite this 
limitation, we believe that this approach represents a powerful method to combine the 
screening for ion channel blockers and the identification of subtle and selective aspects 
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